id|nct_id|mesh_term|downcase_mesh_term|mesh_type
103670441|NCT01953900|Cyclophosphamide|cyclophosphamide|mesh-list
103670442|NCT01953900|Fludarabine|fludarabine|mesh-list
103670443|NCT01953900|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103670444|NCT01953900|Immunologic Factors|immunologic factors|mesh-ancestor
103670445|NCT01953900|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103670446|NCT01953900|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103670447|NCT01953900|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103670448|NCT01953900|Alkylating Agents|alkylating agents|mesh-ancestor
103670449|NCT01953900|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103670450|NCT01953900|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103670451|NCT01953900|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103670656|NCT03528421|Cyclophosphamide|cyclophosphamide|mesh-list
103670657|NCT03528421|Fludarabine|fludarabine|mesh-list
103670658|NCT03528421|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103670659|NCT03528421|Immunologic Factors|immunologic factors|mesh-ancestor
103670660|NCT03528421|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103670661|NCT03528421|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103670662|NCT03528421|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103670663|NCT03528421|Alkylating Agents|alkylating agents|mesh-ancestor
103670664|NCT03528421|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103670665|NCT03528421|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103670666|NCT03528421|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103672515|NCT04581473|Paclitaxel|paclitaxel|mesh-list
103672516|NCT04581473|Irinotecan|irinotecan|mesh-list
103672517|NCT04581473|Apatinib|apatinib|mesh-list
103672518|NCT04581473|Antibodies|antibodies|mesh-list
103672519|NCT04581473|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
103672520|NCT04581473|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103672521|NCT04581473|Tubulin Modulators|tubulin modulators|mesh-ancestor
103672522|NCT04581473|Antimitotic Agents|antimitotic agents|mesh-ancestor
103672523|NCT04581473|Mitosis Modulators|mitosis modulators|mesh-ancestor
103672524|NCT04581473|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103672525|NCT04581473|Immunologic Factors|immunologic factors|mesh-ancestor
103672526|NCT04581473|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103672527|NCT04581473|Topoisomerase I Inhibitors|topoisomerase i inhibitors|mesh-ancestor
103672528|NCT04581473|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
103672529|NCT04581473|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103672530|NCT04581473|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
103677461|NCT02443831|Cyclophosphamide|cyclophosphamide|mesh-list
103677462|NCT02443831|Fludarabine|fludarabine|mesh-list
103677463|NCT02443831|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103677464|NCT02443831|Immunologic Factors|immunologic factors|mesh-ancestor
103677465|NCT02443831|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103677466|NCT02443831|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103677467|NCT02443831|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103677468|NCT02443831|Alkylating Agents|alkylating agents|mesh-ancestor
103677469|NCT02443831|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103677470|NCT02443831|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103677471|NCT02443831|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103677644|NCT05202782|Zanubrutinib|zanubrutinib|mesh-list
103677645|NCT05202782|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103677646|NCT05202782|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
103677647|NCT05202782|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103677648|NCT05202782|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103677824|NCT05191472|Pembrolizumab|pembrolizumab|mesh-list
103677825|NCT05191472|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103677826|NCT05191472|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103677827|NCT05191472|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103677828|NCT05191472|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103680387|NCT04577326|Cyclophosphamide|cyclophosphamide|mesh-list
103680388|NCT04577326|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103680389|NCT04577326|Immunologic Factors|immunologic factors|mesh-ancestor
103680390|NCT04577326|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103680391|NCT04577326|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103680392|NCT04577326|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103680393|NCT04577326|Alkylating Agents|alkylating agents|mesh-ancestor
103680394|NCT04577326|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103680395|NCT04577326|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103680396|NCT04577326|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103388431|NCT05352828|Nivolumab|nivolumab|mesh-list
103612886|NCT03648697|Alkylating Agents|alkylating agents|mesh-ancestor
103615285|NCT03615313|Antibodies|antibodies|mesh-list
103616345|NCT03612739|Azacitidine|azacitidine|mesh-list
103529714|NCT04881240|Immunologic Factors|immunologic factors|mesh-ancestor
103692599|NCT03593109|Immunomodulating Agents|immunomodulating agents|mesh-list
103692600|NCT03593109|Immunologic Factors|immunologic factors|mesh-ancestor
103692601|NCT03593109|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103695722|NCT04412889|Immunomodulating Agents|immunomodulating agents|mesh-list
103695723|NCT04412889|Immunologic Factors|immunologic factors|mesh-ancestor
103695724|NCT04412889|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103697139|NCT03380039|Cyclophosphamide|cyclophosphamide|mesh-list
103697140|NCT03380039|Fludarabine|fludarabine|mesh-list
103697141|NCT03380039|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103697142|NCT03380039|Immunologic Factors|immunologic factors|mesh-ancestor
103697143|NCT03380039|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103697144|NCT03380039|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103697145|NCT03380039|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103697146|NCT03380039|Alkylating Agents|alkylating agents|mesh-ancestor
103697147|NCT03380039|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103697148|NCT03380039|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103697149|NCT03380039|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103420404|NCT04442022|Hormones|hormones|mesh-ancestor
103701277|NCT03322735|Cyclophosphamide|cyclophosphamide|mesh-list
103701278|NCT03322735|Fludarabine|fludarabine|mesh-list
103701279|NCT03322735|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103701280|NCT03322735|Immunologic Factors|immunologic factors|mesh-ancestor
103701281|NCT03322735|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103701282|NCT03322735|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103701283|NCT03322735|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103701284|NCT03322735|Alkylating Agents|alkylating agents|mesh-ancestor
103701285|NCT03322735|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103701286|NCT03322735|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103701287|NCT03322735|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103706333|NCT03344705|Cyclophosphamide|cyclophosphamide|mesh-list
103706334|NCT03344705|Fludarabine|fludarabine|mesh-list
103706335|NCT03344705|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103706336|NCT03344705|Immunologic Factors|immunologic factors|mesh-ancestor
103706337|NCT03344705|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103706338|NCT03344705|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103706339|NCT03344705|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103706340|NCT03344705|Alkylating Agents|alkylating agents|mesh-ancestor
103706341|NCT03344705|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103706342|NCT03344705|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103706343|NCT03344705|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103707636|NCT05016063|Fludarabine|fludarabine|mesh-list
103707637|NCT05016063|Cyclophosphamide|cyclophosphamide|mesh-list
103707638|NCT05016063|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103707639|NCT05016063|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103707640|NCT05016063|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103707641|NCT05016063|Immunologic Factors|immunologic factors|mesh-ancestor
103707642|NCT05016063|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103707643|NCT05016063|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103707644|NCT05016063|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103707645|NCT05016063|Alkylating Agents|alkylating agents|mesh-ancestor
103707646|NCT05016063|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103712357|NCT05179603|Pembrolizumab|pembrolizumab|mesh-list
103712358|NCT05179603|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103712359|NCT05179603|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103712360|NCT05179603|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103712361|NCT05179603|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103718166|NCT04745559|Heptavalent Pneumococcal Conjugate Vaccine|heptavalent pneumococcal conjugate vaccine|mesh-list
103718167|NCT04745559|Immunologic Factors|immunologic factors|mesh-ancestor
103718168|NCT04745559|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103718251|NCT01318317|Plerixafor|plerixafor|mesh-list
103718252|NCT01318317|Rituximab|rituximab|mesh-list
103718253|NCT01318317|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-list
103718254|NCT01318317|Antibodies|antibodies|mesh-list
103718255|NCT01318317|Immunoglobulins|immunoglobulins|mesh-list
103718256|NCT01318317|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
103718257|NCT01318317|Lenograstim|lenograstim|mesh-list
103718258|NCT01318317|Immunologic Factors|immunologic factors|mesh-ancestor
103718259|NCT01318317|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103718260|NCT01318317|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103718261|NCT01318317|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103718262|NCT01318317|Adjuvants, Immunologic|adjuvants, immunologic|mesh-ancestor
103718263|NCT01318317|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
103718264|NCT01318317|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
103718265|NCT01318317|Antiviral Agents|antiviral agents|mesh-ancestor
103718266|NCT01318317|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103721566|NCT05515185|Cyclophosphamide|cyclophosphamide|mesh-list
103721567|NCT05515185|Fludarabine|fludarabine|mesh-list
103721568|NCT05515185|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103721569|NCT05515185|Immunologic Factors|immunologic factors|mesh-ancestor
103721570|NCT05515185|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103721571|NCT05515185|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103721572|NCT05515185|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103721573|NCT05515185|Alkylating Agents|alkylating agents|mesh-ancestor
103721574|NCT05515185|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103721575|NCT05515185|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103721576|NCT05515185|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103721862|NCT03173417|Cyclophosphamide|cyclophosphamide|mesh-list
103721863|NCT03173417|Fludarabine|fludarabine|mesh-list
103721864|NCT03173417|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103721865|NCT03173417|Immunologic Factors|immunologic factors|mesh-ancestor
103721866|NCT03173417|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103721867|NCT03173417|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103721868|NCT03173417|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103721869|NCT03173417|Alkylating Agents|alkylating agents|mesh-ancestor
103721870|NCT03173417|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103721871|NCT03173417|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103721872|NCT03173417|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103724018|NCT05422521|Fluorodeoxyglucose F18|fluorodeoxyglucose f18|mesh-list
103724019|NCT05422521|Radiopharmaceuticals|radiopharmaceuticals|mesh-ancestor
103724020|NCT05422521|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103727622|NCT03182803|Antibodies|antibodies|mesh-list
103727623|NCT03182803|Immunologic Factors|immunologic factors|mesh-ancestor
103727624|NCT03182803|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103728340|NCT05385263|Nivolumab|nivolumab|mesh-list
103728341|NCT05385263|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103728342|NCT05385263|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103728343|NCT05385263|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103728344|NCT05385263|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103729770|NCT02659943|Cyclophosphamide|cyclophosphamide|mesh-list
103729771|NCT02659943|Fludarabine|fludarabine|mesh-list
103729772|NCT02659943|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103729773|NCT02659943|Immunologic Factors|immunologic factors|mesh-ancestor
103729774|NCT02659943|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103729775|NCT02659943|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103729776|NCT02659943|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103729777|NCT02659943|Alkylating Agents|alkylating agents|mesh-ancestor
103729778|NCT02659943|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103729779|NCT02659943|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103729780|NCT02659943|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103737948|NCT05633615|Cyclophosphamide|cyclophosphamide|mesh-list
103737949|NCT05633615|Fludarabine|fludarabine|mesh-list
103737950|NCT05633615|Tisagenlecleucel|tisagenlecleucel|mesh-list
103737951|NCT05633615|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103737952|NCT05633615|Antibodies|antibodies|mesh-list
103737953|NCT05633615|Immunoglobulins|immunoglobulins|mesh-list
103737954|NCT05633615|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
103737955|NCT05633615|Antibodies, Bispecific|antibodies, bispecific|mesh-list
103737956|NCT05633615|Immunoconjugates|immunoconjugates|mesh-list
103737957|NCT05633615|Polatuzumab vedotin|polatuzumab vedotin|mesh-list
103737958|NCT05633615|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103737959|NCT05633615|Immunologic Factors|immunologic factors|mesh-ancestor
103737960|NCT05633615|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103737961|NCT05633615|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103737962|NCT05633615|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103737963|NCT05633615|Alkylating Agents|alkylating agents|mesh-ancestor
103737964|NCT05633615|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103737965|NCT05633615|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103737966|NCT05633615|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103737967|NCT05633615|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103740256|NCT05442580|Cyclophosphamide|cyclophosphamide|mesh-list
103740257|NCT05442580|Fludarabine|fludarabine|mesh-list
103740258|NCT05442580|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103740259|NCT05442580|Immunologic Factors|immunologic factors|mesh-ancestor
103740260|NCT05442580|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103740261|NCT05442580|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103740262|NCT05442580|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103740263|NCT05442580|Alkylating Agents|alkylating agents|mesh-ancestor
103740264|NCT05442580|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103740265|NCT05442580|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103740266|NCT05442580|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103740846|NCT04877613|Cyclophosphamide|cyclophosphamide|mesh-list
103740847|NCT04877613|Fludarabine|fludarabine|mesh-list
103740848|NCT04877613|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103740849|NCT04877613|Immunologic Factors|immunologic factors|mesh-ancestor
103740850|NCT04877613|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103740851|NCT04877613|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103740852|NCT04877613|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103740853|NCT04877613|Alkylating Agents|alkylating agents|mesh-ancestor
103740854|NCT04877613|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103740855|NCT04877613|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103740856|NCT04877613|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103741273|NCT04484012|Acalabrutinib|acalabrutinib|mesh-list
103741274|NCT04484012|Tyrosine Protein Kinase Inhibitors|tyrosine protein kinase inhibitors|mesh-list
103741275|NCT04484012|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103741276|NCT04484012|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
103741277|NCT04484012|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103741278|NCT04484012|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103753079|NCT04796675|Cyclophosphamide|cyclophosphamide|mesh-list
103753080|NCT04796675|Fludarabine|fludarabine|mesh-list
103753081|NCT04796675|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103753082|NCT04796675|Immunologic Factors|immunologic factors|mesh-ancestor
103753083|NCT04796675|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103753084|NCT04796675|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103753085|NCT04796675|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103753086|NCT04796675|Alkylating Agents|alkylating agents|mesh-ancestor
103753087|NCT04796675|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103753088|NCT04796675|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103753089|NCT04796675|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103760293|NCT04134325|Pembrolizumab|pembrolizumab|mesh-list
103760294|NCT04134325|Nivolumab|nivolumab|mesh-list
103760295|NCT04134325|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103760296|NCT04134325|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103760297|NCT04134325|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103760298|NCT04134325|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103761617|NCT04892277|Cyclophosphamide|cyclophosphamide|mesh-list
103761618|NCT04892277|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103761619|NCT04892277|Fludarabine|fludarabine|mesh-list
103761620|NCT04892277|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103761621|NCT04892277|Immunologic Factors|immunologic factors|mesh-ancestor
103761622|NCT04892277|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103761623|NCT04892277|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103761624|NCT04892277|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103761625|NCT04892277|Alkylating Agents|alkylating agents|mesh-ancestor
103761626|NCT04892277|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103761627|NCT04892277|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103761628|NCT04892277|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103762134|NCT05528887|Cyclophosphamide|cyclophosphamide|mesh-list
103762135|NCT05528887|Fludarabine|fludarabine|mesh-list
103762136|NCT05528887|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103762137|NCT05528887|Immunologic Factors|immunologic factors|mesh-ancestor
103762138|NCT05528887|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103762139|NCT05528887|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103762140|NCT05528887|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103762141|NCT05528887|Alkylating Agents|alkylating agents|mesh-ancestor
103762142|NCT05528887|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103762143|NCT05528887|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103762144|NCT05528887|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103762366|NCT05523661|Dasatinib|dasatinib|mesh-list
103762367|NCT05523661|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103762368|NCT05523661|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
103762369|NCT05523661|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103762370|NCT05523661|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103776553|NCT02348216|Cyclophosphamide|cyclophosphamide|mesh-list
103776554|NCT02348216|Fludarabine|fludarabine|mesh-list
103776555|NCT02348216|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103776556|NCT02348216|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103776557|NCT02348216|Immunologic Factors|immunologic factors|mesh-ancestor
103776558|NCT02348216|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103776559|NCT02348216|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103776560|NCT02348216|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103776561|NCT02348216|Alkylating Agents|alkylating agents|mesh-ancestor
103776562|NCT02348216|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103776563|NCT02348216|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103776564|NCT02348216|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103776565|NCT02348216|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103782692|NCT03651128|Dexamethasone|dexamethasone|mesh-list
103782693|NCT03651128|Lenalidomide|lenalidomide|mesh-list
103782694|NCT03651128|Bortezomib|bortezomib|mesh-list
103782695|NCT03651128|Daratumumab|daratumumab|mesh-list
103782696|NCT03651128|Pomalidomide|pomalidomide|mesh-list
103782697|NCT03651128|Ixazomib|ixazomib|mesh-list
103782698|NCT03651128|Elotuzumab|elotuzumab|mesh-list
103782699|NCT03651128|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
103782700|NCT03651128|Antiemetics|antiemetics|mesh-ancestor
103782701|NCT03651128|Autonomic Agents|autonomic agents|mesh-ancestor
103782702|NCT03651128|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103782703|NCT03651128|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103782704|NCT03651128|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
103782705|NCT03651128|Glucocorticoids|glucocorticoids|mesh-ancestor
103782706|NCT03651128|Hormones|hormones|mesh-ancestor
103782707|NCT03651128|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
103782708|NCT03651128|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
103782709|NCT03651128|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103782710|NCT03651128|Immunologic Factors|immunologic factors|mesh-ancestor
103782711|NCT03651128|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
103782712|NCT03651128|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
103782713|NCT03651128|Growth Substances|growth substances|mesh-ancestor
103782714|NCT03651128|Growth Inhibitors|growth inhibitors|mesh-ancestor
103782715|NCT03651128|Protease Inhibitors|protease inhibitors|mesh-ancestor
103782716|NCT03651128|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103782717|NCT03651128|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103786584|NCT04150913|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103786585|NCT04150913|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
103786586|NCT04150913|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103786587|NCT04150913|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103786588|NCT04150913|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103787812|NCT01454596|Aldesleukin|aldesleukin|mesh-list
103787813|NCT01454596|Cyclophosphamide|cyclophosphamide|mesh-list
103787814|NCT01454596|Fludarabine|fludarabine|mesh-list
103787815|NCT01454596|Mitogens|mitogens|mesh-list
103787816|NCT01454596|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103787817|NCT01454596|Immunologic Factors|immunologic factors|mesh-ancestor
103787818|NCT01454596|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103787819|NCT01454596|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103787820|NCT01454596|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103787821|NCT01454596|Alkylating Agents|alkylating agents|mesh-ancestor
103787822|NCT01454596|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103787823|NCT01454596|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103787824|NCT01454596|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103787825|NCT01454596|Mitosis Modulators|mitosis modulators|mesh-ancestor
103787826|NCT01454596|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
103787827|NCT01454596|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
103787828|NCT01454596|Antiviral Agents|antiviral agents|mesh-ancestor
103787829|NCT01454596|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103788002|NCT02215967|Cyclophosphamide|cyclophosphamide|mesh-list
103788003|NCT02215967|Fludarabine|fludarabine|mesh-list
103788004|NCT02215967|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103788005|NCT02215967|Immunologic Factors|immunologic factors|mesh-ancestor
103788006|NCT02215967|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103788007|NCT02215967|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103788008|NCT02215967|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103788009|NCT02215967|Alkylating Agents|alkylating agents|mesh-ancestor
103788010|NCT02215967|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103788011|NCT02215967|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103788012|NCT02215967|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103420715|NCT03448393|Fludarabine|fludarabine|mesh-list
103440938|NCT05364424|Rituximab|rituximab|mesh-list
103563539|NCT04969354|Immunomodulating Agents|immunomodulating agents|mesh-list
103563540|NCT04969354|Immunologic Factors|immunologic factors|mesh-ancestor
103563541|NCT04969354|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103564868|NCT04732845|Cyclophosphamide|cyclophosphamide|mesh-list
103564869|NCT04732845|Fludarabine|fludarabine|mesh-list
103564870|NCT04732845|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103564871|NCT04732845|Immunologic Factors|immunologic factors|mesh-ancestor
103564872|NCT04732845|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103564873|NCT04732845|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103564874|NCT04732845|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103564875|NCT04732845|Alkylating Agents|alkylating agents|mesh-ancestor
103564876|NCT04732845|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103564877|NCT04732845|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103564878|NCT04732845|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103565404|NCT03434769|Cyclophosphamide|cyclophosphamide|mesh-list
103565405|NCT03434769|Fludarabine|fludarabine|mesh-list
103565406|NCT03434769|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103565407|NCT03434769|Immunologic Factors|immunologic factors|mesh-ancestor
103565408|NCT03434769|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103565409|NCT03434769|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103565410|NCT03434769|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103565411|NCT03434769|Alkylating Agents|alkylating agents|mesh-ancestor
103565412|NCT03434769|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103565413|NCT03434769|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103565414|NCT03434769|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103385977|NCT04889716|Obinutuzumab|obinutuzumab|mesh-list
103385978|NCT04889716|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103385979|NCT04889716|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103387302|NCT03277729|Cyclophosphamide|cyclophosphamide|mesh-list
103387303|NCT03277729|Fludarabine|fludarabine|mesh-list
103387304|NCT03277729|Fludarabine phosphate|fludarabine phosphate|mesh-list
103387305|NCT03277729|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103387306|NCT03277729|Immunologic Factors|immunologic factors|mesh-ancestor
103387307|NCT03277729|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103387308|NCT03277729|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103387309|NCT03277729|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103387310|NCT03277729|Alkylating Agents|alkylating agents|mesh-ancestor
103387311|NCT03277729|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103387312|NCT03277729|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103387313|NCT03277729|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103387314|NCT03277729|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103387315|NCT03277729|Antimetabolites|antimetabolites|mesh-ancestor
103388432|NCT05352828|Fludarabine|fludarabine|mesh-list
103388433|NCT05352828|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103388434|NCT05352828|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103388435|NCT05352828|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103388436|NCT05352828|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103388437|NCT05352828|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103388438|NCT05352828|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103388439|NCT05352828|Alkylating Agents|alkylating agents|mesh-ancestor
103804289|NCT04690192|Gemcitabine|gemcitabine|mesh-list
103804290|NCT04690192|Melphalan|melphalan|mesh-list
103804291|NCT04690192|Busulfan|busulfan|mesh-list
103804292|NCT04690192|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103804293|NCT04690192|Antimetabolites|antimetabolites|mesh-ancestor
103804294|NCT04690192|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103804295|NCT04690192|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103804296|NCT04690192|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103804297|NCT04690192|Alkylating Agents|alkylating agents|mesh-ancestor
103804298|NCT04690192|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103804299|NCT04690192|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103804300|NCT04690192|Immunologic Factors|immunologic factors|mesh-ancestor
103804301|NCT04690192|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103804467|NCT04049513|Cyclophosphamide|cyclophosphamide|mesh-list
103804468|NCT04049513|Fludarabine|fludarabine|mesh-list
103804469|NCT04049513|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103804470|NCT04049513|Immunologic Factors|immunologic factors|mesh-ancestor
103804471|NCT04049513|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103804472|NCT04049513|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103804473|NCT04049513|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103804474|NCT04049513|Alkylating Agents|alkylating agents|mesh-ancestor
103804475|NCT04049513|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103804476|NCT04049513|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103804477|NCT04049513|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103804874|NCT03103971|Cyclophosphamide|cyclophosphamide|mesh-list
103804875|NCT03103971|Fludarabine|fludarabine|mesh-list
103804876|NCT03103971|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103804877|NCT03103971|Immunologic Factors|immunologic factors|mesh-ancestor
103804878|NCT03103971|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103804879|NCT03103971|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103804880|NCT03103971|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103804881|NCT03103971|Alkylating Agents|alkylating agents|mesh-ancestor
103804882|NCT03103971|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103804883|NCT03103971|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103804884|NCT03103971|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103810978|NCT05483491|Aldesleukin|aldesleukin|mesh-list
103810979|NCT05483491|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103810980|NCT05483491|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
103810981|NCT05483491|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
103810982|NCT05483491|Antiviral Agents|antiviral agents|mesh-ancestor
103810983|NCT05483491|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103559050|NCT02194374|Cyclophosphamide|cyclophosphamide|mesh-list
103559051|NCT02194374|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103559052|NCT02194374|Rituximab|rituximab|mesh-list
103559053|NCT02194374|Fludarabine|fludarabine|mesh-list
103559054|NCT02194374|Fludarabine phosphate|fludarabine phosphate|mesh-list
103559055|NCT02194374|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103559056|NCT02194374|Immunologic Factors|immunologic factors|mesh-ancestor
103559057|NCT02194374|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103559058|NCT02194374|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103559059|NCT02194374|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103559060|NCT02194374|Alkylating Agents|alkylating agents|mesh-ancestor
103559061|NCT02194374|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103559062|NCT02194374|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103559063|NCT02194374|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103559064|NCT02194374|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103559065|NCT02194374|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103559066|NCT02194374|Antimetabolites|antimetabolites|mesh-ancestor
103560329|NCT02905188|Cyclophosphamide|cyclophosphamide|mesh-list
103560330|NCT02905188|Fludarabine|fludarabine|mesh-list
103560331|NCT02905188|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103560332|NCT02905188|Immunologic Factors|immunologic factors|mesh-ancestor
103560333|NCT02905188|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103560334|NCT02905188|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103560335|NCT02905188|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103560336|NCT02905188|Alkylating Agents|alkylating agents|mesh-ancestor
103560337|NCT02905188|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103560338|NCT02905188|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103560339|NCT02905188|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103560516|NCT04952272|CPG-oligonucleotide|cpg-oligonucleotide|mesh-list
103560517|NCT04952272|Adjuvants, Immunologic|adjuvants, immunologic|mesh-ancestor
103560518|NCT04952272|Immunologic Factors|immunologic factors|mesh-ancestor
103560519|NCT04952272|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103459246|NCT04823091|Cyclophosphamide|cyclophosphamide|mesh-list
103459247|NCT04823091|Fludarabine|fludarabine|mesh-list
103459248|NCT04823091|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103459249|NCT04823091|Immunologic Factors|immunologic factors|mesh-ancestor
103459250|NCT04823091|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103459251|NCT04823091|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103459252|NCT04823091|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103459253|NCT04823091|Alkylating Agents|alkylating agents|mesh-ancestor
103459254|NCT04823091|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103459255|NCT04823091|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103459256|NCT04823091|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103460286|NCT03814447|Cyclophosphamide|cyclophosphamide|mesh-list
103460287|NCT03814447|Fludarabine|fludarabine|mesh-list
103460288|NCT03814447|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103460289|NCT03814447|Immunologic Factors|immunologic factors|mesh-ancestor
103460290|NCT03814447|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103460291|NCT03814447|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103460292|NCT03814447|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103460293|NCT03814447|Alkylating Agents|alkylating agents|mesh-ancestor
103460294|NCT03814447|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103460295|NCT03814447|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103460296|NCT03814447|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103466080|NCT03916679|Cyclophosphamide|cyclophosphamide|mesh-list
103466081|NCT03916679|Fludarabine|fludarabine|mesh-list
103466082|NCT03916679|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103466083|NCT03916679|Immunologic Factors|immunologic factors|mesh-ancestor
103466084|NCT03916679|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103466085|NCT03916679|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103466086|NCT03916679|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103466087|NCT03916679|Alkylating Agents|alkylating agents|mesh-ancestor
103466088|NCT03916679|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103466089|NCT03916679|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103466090|NCT03916679|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103394854|NCT02431988|Cyclophosphamide|cyclophosphamide|mesh-list
103394855|NCT02431988|Fludarabine|fludarabine|mesh-list
103394856|NCT02431988|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103394857|NCT02431988|Immunologic Factors|immunologic factors|mesh-ancestor
103394858|NCT02431988|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103394859|NCT02431988|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103394860|NCT02431988|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103394861|NCT02431988|Alkylating Agents|alkylating agents|mesh-ancestor
103394862|NCT02431988|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103394863|NCT02431988|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103394864|NCT02431988|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103399005|NCT05404048|Atezolizumab|atezolizumab|mesh-list
103399006|NCT05404048|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103399007|NCT05404048|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103399008|NCT05404048|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103399009|NCT05404048|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103256424|NCT04119024|Analgesics|analgesics|mesh-ancestor
103569068|NCT04850560|Decitabine|decitabine|mesh-list
103569069|NCT04850560|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103569070|NCT04850560|Antimetabolites|antimetabolites|mesh-ancestor
103569071|NCT04850560|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103569072|NCT04850560|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103569073|NCT04850560|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103570967|NCT04697940|Cyclophosphamide|cyclophosphamide|mesh-list
103570968|NCT04697940|Fludarabine|fludarabine|mesh-list
103570969|NCT04697940|Fludarabine phosphate|fludarabine phosphate|mesh-list
103570970|NCT04697940|Decitabine|decitabine|mesh-list
103570971|NCT04697940|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103570972|NCT04697940|Immunologic Factors|immunologic factors|mesh-ancestor
103570973|NCT04697940|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103570974|NCT04697940|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103570975|NCT04697940|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103570976|NCT04697940|Alkylating Agents|alkylating agents|mesh-ancestor
103570977|NCT04697940|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103570978|NCT04697940|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103570979|NCT04697940|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103570980|NCT04697940|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103570981|NCT04697940|Antimetabolites|antimetabolites|mesh-ancestor
103570982|NCT04697940|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103581913|NCT04703686|Obinutuzumab|obinutuzumab|mesh-list
103581914|NCT04703686|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103581915|NCT04703686|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103588595|NCT04706936|Cyclophosphamide|cyclophosphamide|mesh-list
103588596|NCT04706936|Fludarabine|fludarabine|mesh-list
103588597|NCT04706936|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103588598|NCT04706936|Immunologic Factors|immunologic factors|mesh-ancestor
103588599|NCT04706936|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103588600|NCT04706936|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103588601|NCT04706936|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103588602|NCT04706936|Alkylating Agents|alkylating agents|mesh-ancestor
103588603|NCT04706936|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103588604|NCT04706936|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103588605|NCT04706936|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103590340|NCT05393804|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
103590341|NCT05393804|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103590342|NCT05393804|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103590914|NCT02601313|Cyclophosphamide|cyclophosphamide|mesh-list
103590915|NCT02601313|Fludarabine|fludarabine|mesh-list
103590916|NCT02601313|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103590917|NCT02601313|Brexucabtagene autoleucel|brexucabtagene autoleucel|mesh-list
103590918|NCT02601313|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103590919|NCT02601313|Immunologic Factors|immunologic factors|mesh-ancestor
103590920|NCT02601313|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103590921|NCT02601313|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103590922|NCT02601313|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103590923|NCT02601313|Alkylating Agents|alkylating agents|mesh-ancestor
103590924|NCT02601313|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103590925|NCT02601313|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103590926|NCT02601313|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103590927|NCT02601313|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103594812|NCT03710421|Cyclophosphamide|cyclophosphamide|mesh-list
103594813|NCT03710421|Fludarabine|fludarabine|mesh-list
103594814|NCT03710421|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103594815|NCT03710421|Immunologic Factors|immunologic factors|mesh-ancestor
103594816|NCT03710421|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103594817|NCT03710421|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103594818|NCT03710421|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103594819|NCT03710421|Alkylating Agents|alkylating agents|mesh-ancestor
103594820|NCT03710421|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103594821|NCT03710421|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103594822|NCT03710421|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103595741|NCT03919526|Cyclophosphamide|cyclophosphamide|mesh-list
103595742|NCT03919526|Fludarabine|fludarabine|mesh-list
103595743|NCT03919526|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103595744|NCT03919526|Immunologic Factors|immunologic factors|mesh-ancestor
103595745|NCT03919526|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103595746|NCT03919526|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103595747|NCT03919526|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103595748|NCT03919526|Alkylating Agents|alkylating agents|mesh-ancestor
103595749|NCT03919526|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103595750|NCT03919526|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103595751|NCT03919526|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103598620|NCT03208556|Cyclophosphamide|cyclophosphamide|mesh-list
103598621|NCT03208556|Fludarabine|fludarabine|mesh-list
103598622|NCT03208556|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103598623|NCT03208556|Immunologic Factors|immunologic factors|mesh-ancestor
103598624|NCT03208556|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103598625|NCT03208556|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103598626|NCT03208556|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103598627|NCT03208556|Alkylating Agents|alkylating agents|mesh-ancestor
103598628|NCT03208556|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103598629|NCT03208556|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103598630|NCT03208556|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103599026|NCT02303821|Cytarabine|cytarabine|mesh-list
103599027|NCT02303821|Dexamethasone|dexamethasone|mesh-list
103599028|NCT02303821|Hydrocortisone|hydrocortisone|mesh-list
103599029|NCT02303821|Cyclophosphamide|cyclophosphamide|mesh-list
103599030|NCT02303821|Methotrexate|methotrexate|mesh-list
103599031|NCT02303821|Vincristine|vincristine|mesh-list
103599032|NCT02303821|Daunorubicin|daunorubicin|mesh-list
103599033|NCT02303821|Asparaginase|asparaginase|mesh-list
103599034|NCT02303821|Mitoxantrone|mitoxantrone|mesh-list
103599035|NCT02303821|Mercaptopurine|mercaptopurine|mesh-list
103599036|NCT02303821|Pegaspargase|pegaspargase|mesh-list
103599037|NCT02303821|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103599038|NCT02303821|Immunologic Factors|immunologic factors|mesh-ancestor
103599039|NCT02303821|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103599040|NCT02303821|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103599041|NCT02303821|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103599042|NCT02303821|Alkylating Agents|alkylating agents|mesh-ancestor
103599043|NCT02303821|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103599044|NCT02303821|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103599045|NCT02303821|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103599046|NCT02303821|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
103599047|NCT02303821|Antiemetics|antiemetics|mesh-ancestor
103599048|NCT02303821|Autonomic Agents|autonomic agents|mesh-ancestor
103599049|NCT02303821|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103599050|NCT02303821|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
103599051|NCT02303821|Glucocorticoids|glucocorticoids|mesh-ancestor
103599052|NCT02303821|Hormones|hormones|mesh-ancestor
103599053|NCT02303821|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
103599054|NCT02303821|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
103599055|NCT02303821|Abortifacient Agents, Nonsteroidal|abortifacient agents, nonsteroidal|mesh-ancestor
103599056|NCT02303821|Abortifacient Agents|abortifacient agents|mesh-ancestor
103599057|NCT02303821|Reproductive Control Agents|reproductive control agents|mesh-ancestor
103599058|NCT02303821|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103599059|NCT02303821|Antimetabolites|antimetabolites|mesh-ancestor
103599060|NCT02303821|Dermatologic Agents|dermatologic agents|mesh-ancestor
103599061|NCT02303821|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103599062|NCT02303821|Folic Acid Antagonists|folic acid antagonists|mesh-ancestor
103599063|NCT02303821|Nucleic Acid Synthesis Inhibitors|nucleic acid synthesis inhibitors|mesh-ancestor
103599064|NCT02303821|Antiviral Agents|antiviral agents|mesh-ancestor
103599065|NCT02303821|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103599066|NCT02303821|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
103599067|NCT02303821|Tubulin Modulators|tubulin modulators|mesh-ancestor
103599068|NCT02303821|Antimitotic Agents|antimitotic agents|mesh-ancestor
103599069|NCT02303821|Mitosis Modulators|mitosis modulators|mesh-ancestor
103599070|NCT02303821|Antibiotics, Antineoplastic|antibiotics, antineoplastic|mesh-ancestor
103599071|NCT02303821|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
103599072|NCT02303821|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
103599073|NCT02303821|Analgesics|analgesics|mesh-ancestor
103599074|NCT02303821|Sensory System Agents|sensory system agents|mesh-ancestor
103600215|NCT02439788|Cyclophosphamide|cyclophosphamide|mesh-list
103600216|NCT02439788|Fludarabine|fludarabine|mesh-list
103600217|NCT02439788|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103600218|NCT02439788|Immunologic Factors|immunologic factors|mesh-ancestor
103600219|NCT02439788|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103600220|NCT02439788|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103600221|NCT02439788|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103600222|NCT02439788|Alkylating Agents|alkylating agents|mesh-ancestor
103600223|NCT02439788|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103600224|NCT02439788|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103600225|NCT02439788|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103604765|NCT03070327|Cyclophosphamide|cyclophosphamide|mesh-list
103604766|NCT03070327|Lenalidomide|lenalidomide|mesh-list
103604767|NCT03070327|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103604768|NCT03070327|Immunologic Factors|immunologic factors|mesh-ancestor
103604769|NCT03070327|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103604770|NCT03070327|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103604771|NCT03070327|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103604772|NCT03070327|Alkylating Agents|alkylating agents|mesh-ancestor
103604773|NCT03070327|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103604774|NCT03070327|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103604775|NCT03070327|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103604776|NCT03070327|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
103604777|NCT03070327|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
103604778|NCT03070327|Growth Substances|growth substances|mesh-ancestor
103604779|NCT03070327|Growth Inhibitors|growth inhibitors|mesh-ancestor
103608532|NCT05155215|Cyclophosphamide|cyclophosphamide|mesh-list
103608533|NCT05155215|Fludarabine|fludarabine|mesh-list
103608534|NCT05155215|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103608535|NCT05155215|Immunologic Factors|immunologic factors|mesh-ancestor
103608536|NCT05155215|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103608537|NCT05155215|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103608538|NCT05155215|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103608539|NCT05155215|Alkylating Agents|alkylating agents|mesh-ancestor
103608540|NCT05155215|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103608541|NCT05155215|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103608542|NCT05155215|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103612879|NCT03648697|Cyclophosphamide|cyclophosphamide|mesh-list
103612880|NCT03648697|Fludarabine|fludarabine|mesh-list
103612881|NCT03648697|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103612882|NCT03648697|Immunologic Factors|immunologic factors|mesh-ancestor
103612883|NCT03648697|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103612884|NCT03648697|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103612885|NCT03648697|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103612887|NCT03648697|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103612888|NCT03648697|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103612889|NCT03648697|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103613771|NCT03468153|Immunomodulating Agents|immunomodulating agents|mesh-list
103613772|NCT03468153|Immunologic Factors|immunologic factors|mesh-ancestor
103613773|NCT03468153|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103613920|NCT02529813|Cyclophosphamide|cyclophosphamide|mesh-list
103613921|NCT02529813|Fludarabine|fludarabine|mesh-list
103613922|NCT02529813|Fludarabine phosphate|fludarabine phosphate|mesh-list
103613923|NCT02529813|Tisagenlecleucel|tisagenlecleucel|mesh-list
103613924|NCT02529813|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103613925|NCT02529813|Immunologic Factors|immunologic factors|mesh-ancestor
103613926|NCT02529813|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103613927|NCT02529813|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103613928|NCT02529813|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103613929|NCT02529813|Alkylating Agents|alkylating agents|mesh-ancestor
103613930|NCT02529813|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103613931|NCT02529813|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103613932|NCT02529813|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103613933|NCT02529813|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103613934|NCT02529813|Antimetabolites|antimetabolites|mesh-ancestor
103613935|NCT02529813|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103615286|NCT03615313|Immunologic Factors|immunologic factors|mesh-ancestor
103615287|NCT03615313|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103616346|NCT03612739|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103616347|NCT03612739|Antimetabolites|antimetabolites|mesh-ancestor
103616348|NCT03612739|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103616349|NCT03612739|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103616350|NCT03612739|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103618860|NCT03939026|Cyclophosphamide|cyclophosphamide|mesh-list
103618861|NCT03939026|Fludarabine|fludarabine|mesh-list
103618862|NCT03939026|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103618863|NCT03939026|Immunologic Factors|immunologic factors|mesh-ancestor
103618864|NCT03939026|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103618865|NCT03939026|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103618866|NCT03939026|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103618867|NCT03939026|Alkylating Agents|alkylating agents|mesh-ancestor
103618868|NCT03939026|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103618869|NCT03939026|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103618870|NCT03939026|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103619125|NCT03142646|Cyclophosphamide|cyclophosphamide|mesh-list
103619126|NCT03142646|Fludarabine|fludarabine|mesh-list
103619127|NCT03142646|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103619128|NCT03142646|Immunologic Factors|immunologic factors|mesh-ancestor
103619129|NCT03142646|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103619130|NCT03142646|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103619131|NCT03142646|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103619132|NCT03142646|Alkylating Agents|alkylating agents|mesh-ancestor
103619133|NCT03142646|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103619134|NCT03142646|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103619135|NCT03142646|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103622246|NCT04545762|Cyclophosphamide|cyclophosphamide|mesh-list
103622247|NCT04545762|Fludarabine|fludarabine|mesh-list
103622248|NCT04545762|Fludarabine phosphate|fludarabine phosphate|mesh-list
103622249|NCT04545762|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103622250|NCT04545762|Immunologic Factors|immunologic factors|mesh-ancestor
103622251|NCT04545762|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103622252|NCT04545762|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103622253|NCT04545762|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103622254|NCT04545762|Alkylating Agents|alkylating agents|mesh-ancestor
103622255|NCT04545762|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103622256|NCT04545762|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103622257|NCT04545762|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103622258|NCT04545762|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103622259|NCT04545762|Antimetabolites|antimetabolites|mesh-ancestor
103622320|NCT04419909|Tisagenlecleucel|tisagenlecleucel|mesh-list
103622321|NCT04419909|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103622322|NCT04419909|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103629969|NCT02981628|Calcium, Dietary|calcium, dietary|mesh-list
103629970|NCT02981628|Leucovorin|leucovorin|mesh-list
103629971|NCT02981628|Folic Acid|folic acid|mesh-list
103629972|NCT02981628|Cytarabine|cytarabine|mesh-list
103629973|NCT02981628|Cyclophosphamide|cyclophosphamide|mesh-list
103629974|NCT02981628|Methotrexate|methotrexate|mesh-list
103629975|NCT02981628|Vincristine|vincristine|mesh-list
103629976|NCT02981628|Asparaginase|asparaginase|mesh-list
103629977|NCT02981628|Pegaspargase|pegaspargase|mesh-list
103629978|NCT02981628|Inotuzumab Ozogamicin|inotuzumab ozogamicin|mesh-list
103629979|NCT02981628|Calcium|calcium|mesh-list
103629980|NCT02981628|Levoleucovorin|levoleucovorin|mesh-list
103629981|NCT02981628|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103629982|NCT02981628|Immunologic Factors|immunologic factors|mesh-ancestor
103629983|NCT02981628|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103629984|NCT02981628|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103629985|NCT02981628|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103629986|NCT02981628|Alkylating Agents|alkylating agents|mesh-ancestor
103629987|NCT02981628|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103629988|NCT02981628|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103629989|NCT02981628|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103629990|NCT02981628|Calcium-Regulating Hormones and Agents|calcium-regulating hormones and agents|mesh-ancestor
103629991|NCT02981628|Bone Density Conservation Agents|bone density conservation agents|mesh-ancestor
103629992|NCT02981628|Abortifacient Agents, Nonsteroidal|abortifacient agents, nonsteroidal|mesh-ancestor
103629993|NCT02981628|Abortifacient Agents|abortifacient agents|mesh-ancestor
103629994|NCT02981628|Reproductive Control Agents|reproductive control agents|mesh-ancestor
103629995|NCT02981628|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103629996|NCT02981628|Antimetabolites|antimetabolites|mesh-ancestor
103629997|NCT02981628|Dermatologic Agents|dermatologic agents|mesh-ancestor
103629998|NCT02981628|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103629999|NCT02981628|Folic Acid Antagonists|folic acid antagonists|mesh-ancestor
103630000|NCT02981628|Nucleic Acid Synthesis Inhibitors|nucleic acid synthesis inhibitors|mesh-ancestor
103630001|NCT02981628|Antiviral Agents|antiviral agents|mesh-ancestor
103630002|NCT02981628|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103630003|NCT02981628|Antidotes|antidotes|mesh-ancestor
103630004|NCT02981628|Protective Agents|protective agents|mesh-ancestor
103630005|NCT02981628|Vitamin B Complex|vitamin b complex|mesh-ancestor
103630006|NCT02981628|Vitamins|vitamins|mesh-ancestor
103630007|NCT02981628|Micronutrients|micronutrients|mesh-ancestor
103630008|NCT02981628|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
103630009|NCT02981628|Tubulin Modulators|tubulin modulators|mesh-ancestor
103630010|NCT02981628|Antimitotic Agents|antimitotic agents|mesh-ancestor
103630011|NCT02981628|Mitosis Modulators|mitosis modulators|mesh-ancestor
103630012|NCT02981628|Hematinics|hematinics|mesh-ancestor
103630013|NCT02981628|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103630014|NCT02981628|Antibiotics, Antineoplastic|antibiotics, antineoplastic|mesh-ancestor
103630015|NCT02981628|Immunotoxins|immunotoxins|mesh-ancestor
103630016|NCT02981628|Immunoconjugates|immunoconjugates|mesh-ancestor
103632328|NCT03302403|Cyclophosphamide|cyclophosphamide|mesh-list
103632329|NCT03302403|Fludarabine|fludarabine|mesh-list
103632330|NCT03302403|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103632331|NCT03302403|Immunologic Factors|immunologic factors|mesh-ancestor
103632332|NCT03302403|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103632333|NCT03302403|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103632334|NCT03302403|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103632335|NCT03302403|Alkylating Agents|alkylating agents|mesh-ancestor
103632336|NCT03302403|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103632337|NCT03302403|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103632338|NCT03302403|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103637786|NCT03252171|Immunomodulating Agents|immunomodulating agents|mesh-list
103637787|NCT03252171|Immunologic Factors|immunologic factors|mesh-ancestor
103637788|NCT03252171|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103639244|NCT05354375|Immunomodulating Agents|immunomodulating agents|mesh-list
103639245|NCT05354375|Immunologic Factors|immunologic factors|mesh-ancestor
103639246|NCT05354375|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103639989|NCT04715191|Cyclophosphamide|cyclophosphamide|mesh-list
103639990|NCT04715191|Fludarabine|fludarabine|mesh-list
103639991|NCT04715191|Fludarabine phosphate|fludarabine phosphate|mesh-list
103639992|NCT04715191|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103639993|NCT04715191|Immunologic Factors|immunologic factors|mesh-ancestor
103639994|NCT04715191|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103639995|NCT04715191|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103639996|NCT04715191|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103639997|NCT04715191|Alkylating Agents|alkylating agents|mesh-ancestor
103639998|NCT04715191|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103639999|NCT04715191|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103640000|NCT04715191|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103640001|NCT04715191|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103640002|NCT04715191|Antimetabolites|antimetabolites|mesh-ancestor
103652594|NCT02706405|Cyclophosphamide|cyclophosphamide|mesh-list
103652595|NCT02706405|Fludarabine|fludarabine|mesh-list
103652596|NCT02706405|Durvalumab|durvalumab|mesh-list
103652597|NCT02706405|Immunoglobulins|immunoglobulins|mesh-list
103652598|NCT02706405|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
103652599|NCT02706405|Immunoglobulin G|immunoglobulin g|mesh-list
103652600|NCT02706405|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103652601|NCT02706405|Immunologic Factors|immunologic factors|mesh-ancestor
103652602|NCT02706405|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103652603|NCT02706405|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103652604|NCT02706405|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103652605|NCT02706405|Alkylating Agents|alkylating agents|mesh-ancestor
103652606|NCT02706405|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103652607|NCT02706405|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103652608|NCT02706405|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103652609|NCT02706405|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103652833|NCT02761915|Cyclophosphamide|cyclophosphamide|mesh-list
103652834|NCT02761915|Fludarabine|fludarabine|mesh-list
103652835|NCT02761915|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103652836|NCT02761915|Immunologic Factors|immunologic factors|mesh-ancestor
103652837|NCT02761915|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103652838|NCT02761915|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103652839|NCT02761915|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103652840|NCT02761915|Alkylating Agents|alkylating agents|mesh-ancestor
103652841|NCT02761915|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103652842|NCT02761915|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103652843|NCT02761915|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103655880|NCT05626322|Lenalidomide|lenalidomide|mesh-list
103655881|NCT05626322|Immunologic Factors|immunologic factors|mesh-ancestor
103655882|NCT05626322|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103655883|NCT05626322|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
103655884|NCT05626322|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
103655885|NCT05626322|Growth Substances|growth substances|mesh-ancestor
103655886|NCT05626322|Growth Inhibitors|growth inhibitors|mesh-ancestor
103655887|NCT05626322|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103656867|NCT02107963|Cyclophosphamide|cyclophosphamide|mesh-list
103656868|NCT02107963|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103656869|NCT02107963|Immunologic Factors|immunologic factors|mesh-ancestor
103656870|NCT02107963|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103656871|NCT02107963|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103656872|NCT02107963|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103656873|NCT02107963|Alkylating Agents|alkylating agents|mesh-ancestor
103656874|NCT02107963|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103656875|NCT02107963|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103656876|NCT02107963|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103446117|NCT03874897|Antibodies|antibodies|mesh-list
103446118|NCT03874897|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
103446119|NCT03874897|Immunologic Factors|immunologic factors|mesh-ancestor
103446120|NCT03874897|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103449691|NCT00924326|Vidarabine|vidarabine|mesh-list
103449692|NCT00924326|Aldesleukin|aldesleukin|mesh-list
103449693|NCT00924326|Cyclophosphamide|cyclophosphamide|mesh-list
103449694|NCT00924326|Fludarabine|fludarabine|mesh-list
103449695|NCT00924326|Fludarabine phosphate|fludarabine phosphate|mesh-list
103449696|NCT00924326|Interleukin-2|interleukin-2|mesh-list
103449697|NCT00924326|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103449698|NCT00924326|Immunologic Factors|immunologic factors|mesh-ancestor
103449699|NCT00924326|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103449700|NCT00924326|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103449701|NCT00924326|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103449702|NCT00924326|Alkylating Agents|alkylating agents|mesh-ancestor
103449703|NCT00924326|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103449704|NCT00924326|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103449705|NCT00924326|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103449706|NCT00924326|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103449707|NCT00924326|Antimetabolites|antimetabolites|mesh-ancestor
103449708|NCT00924326|Antiviral Agents|antiviral agents|mesh-ancestor
103449709|NCT00924326|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103449710|NCT00924326|Analgesics, Non-Narcotic|analgesics, non-narcotic|mesh-ancestor
103449711|NCT00924326|Analgesics|analgesics|mesh-ancestor
103449712|NCT00924326|Sensory System Agents|sensory system agents|mesh-ancestor
103449713|NCT00924326|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103449714|NCT00924326|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
103449715|NCT00924326|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
103452078|NCT03716856|Cyclophosphamide|cyclophosphamide|mesh-list
103452079|NCT03716856|Fludarabine|fludarabine|mesh-list
103452080|NCT03716856|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103452081|NCT03716856|Immunologic Factors|immunologic factors|mesh-ancestor
103452082|NCT03716856|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103452083|NCT03716856|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103452084|NCT03716856|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103452085|NCT03716856|Alkylating Agents|alkylating agents|mesh-ancestor
103452086|NCT03716856|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103452087|NCT03716856|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103452088|NCT03716856|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103297979|NCT05225831|Cyclophosphamide|cyclophosphamide|mesh-list
103297980|NCT05225831|Fludarabine|fludarabine|mesh-list
103297981|NCT05225831|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103297982|NCT05225831|Immunologic Factors|immunologic factors|mesh-ancestor
103297983|NCT05225831|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103297984|NCT05225831|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103297985|NCT05225831|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103297986|NCT05225831|Alkylating Agents|alkylating agents|mesh-ancestor
103297987|NCT05225831|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103297988|NCT05225831|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103297989|NCT05225831|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103300430|NCT05081479|Acetylcysteine|acetylcysteine|mesh-list
103300431|NCT05081479|N-monoacetylcystine|n-monoacetylcystine|mesh-list
103300432|NCT05081479|Antiviral Agents|antiviral agents|mesh-ancestor
103300433|NCT05081479|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103300434|NCT05081479|Expectorants|expectorants|mesh-ancestor
103300435|NCT05081479|Respiratory System Agents|respiratory system agents|mesh-ancestor
103300436|NCT05081479|Free Radical Scavengers|free radical scavengers|mesh-ancestor
103300437|NCT05081479|Antioxidants|antioxidants|mesh-ancestor
103300438|NCT05081479|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103300439|NCT05081479|Protective Agents|protective agents|mesh-ancestor
103300440|NCT05081479|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103300441|NCT05081479|Antidotes|antidotes|mesh-ancestor
103301974|NCT04648046|Cyclophosphamide|cyclophosphamide|mesh-list
103301975|NCT04648046|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103301976|NCT04648046|Immunologic Factors|immunologic factors|mesh-ancestor
103301977|NCT04648046|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103301978|NCT04648046|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103301979|NCT04648046|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103301980|NCT04648046|Alkylating Agents|alkylating agents|mesh-ancestor
103301981|NCT04648046|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103301982|NCT04648046|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103301983|NCT04648046|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103302126|NCT04510051|Cyclophosphamide|cyclophosphamide|mesh-list
103302127|NCT04510051|Fludarabine|fludarabine|mesh-list
103302128|NCT04510051|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103302129|NCT04510051|Immunologic Factors|immunologic factors|mesh-ancestor
103302130|NCT04510051|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103302131|NCT04510051|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103302132|NCT04510051|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103302133|NCT04510051|Alkylating Agents|alkylating agents|mesh-ancestor
103302134|NCT04510051|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103302135|NCT04510051|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103302136|NCT04510051|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103305179|NCT03502577|Cyclophosphamide|cyclophosphamide|mesh-list
103305180|NCT03502577|Fludarabine|fludarabine|mesh-list
103305181|NCT03502577|Gamma Secretase Inhibitors and Modulators|gamma secretase inhibitors and modulators|mesh-list
103305182|NCT03502577|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103305183|NCT03502577|Immunologic Factors|immunologic factors|mesh-ancestor
103305184|NCT03502577|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103305185|NCT03502577|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103305186|NCT03502577|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103305187|NCT03502577|Alkylating Agents|alkylating agents|mesh-ancestor
103305188|NCT03502577|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103305189|NCT03502577|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103305190|NCT03502577|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103305191|NCT03502577|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103416480|NCT03338972|Cyclophosphamide|cyclophosphamide|mesh-list
103416481|NCT03338972|Fludarabine|fludarabine|mesh-list
103416482|NCT03338972|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103416483|NCT03338972|Immunologic Factors|immunologic factors|mesh-ancestor
103416484|NCT03338972|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103416485|NCT03338972|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103416486|NCT03338972|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103416487|NCT03338972|Alkylating Agents|alkylating agents|mesh-ancestor
103416488|NCT03338972|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103416489|NCT03338972|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103416490|NCT03338972|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103420262|NCT04633148|Cyclophosphamide|cyclophosphamide|mesh-list
103420263|NCT04633148|Fludarabine|fludarabine|mesh-list
103420264|NCT04633148|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103420265|NCT04633148|Immunologic Factors|immunologic factors|mesh-ancestor
103420266|NCT04633148|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103420267|NCT04633148|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103420268|NCT04633148|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103420269|NCT04633148|Alkylating Agents|alkylating agents|mesh-ancestor
103420270|NCT04633148|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103420271|NCT04633148|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103420272|NCT04633148|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103420390|NCT04442022|Dexamethasone|dexamethasone|mesh-list
103420391|NCT04442022|Rituximab|rituximab|mesh-list
103420392|NCT04442022|Gemcitabine|gemcitabine|mesh-list
103420393|NCT04442022|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103420394|NCT04442022|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103420395|NCT04442022|Immunologic Factors|immunologic factors|mesh-ancestor
103420396|NCT04442022|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103420397|NCT04442022|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103420398|NCT04442022|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
103420399|NCT04442022|Antiemetics|antiemetics|mesh-ancestor
103420400|NCT04442022|Autonomic Agents|autonomic agents|mesh-ancestor
103420401|NCT04442022|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103420402|NCT04442022|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
103420403|NCT04442022|Glucocorticoids|glucocorticoids|mesh-ancestor
103420405|NCT04442022|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
103420406|NCT04442022|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
103420407|NCT04442022|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103420408|NCT04442022|Antimetabolites|antimetabolites|mesh-ancestor
103420409|NCT04442022|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103420537|NCT04196491|Cyclophosphamide|cyclophosphamide|mesh-list
103420538|NCT04196491|Fludarabine|fludarabine|mesh-list
103420539|NCT04196491|Lenalidomide|lenalidomide|mesh-list
103420540|NCT04196491|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103420541|NCT04196491|Immunologic Factors|immunologic factors|mesh-ancestor
103420542|NCT04196491|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103420543|NCT04196491|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103420544|NCT04196491|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103420545|NCT04196491|Alkylating Agents|alkylating agents|mesh-ancestor
103420546|NCT04196491|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103420547|NCT04196491|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103420548|NCT04196491|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103420549|NCT04196491|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
103420550|NCT04196491|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
103420551|NCT04196491|Growth Substances|growth substances|mesh-ancestor
103420552|NCT04196491|Growth Inhibitors|growth inhibitors|mesh-ancestor
103420714|NCT03448393|Cyclophosphamide|cyclophosphamide|mesh-list
103420716|NCT03448393|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103420717|NCT03448393|Immunologic Factors|immunologic factors|mesh-ancestor
103420718|NCT03448393|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103420719|NCT03448393|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103420720|NCT03448393|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103420721|NCT03448393|Alkylating Agents|alkylating agents|mesh-ancestor
103420722|NCT03448393|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103420723|NCT03448393|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103420724|NCT03448393|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103427780|NCT04077866|Temozolomide|temozolomide|mesh-list
103427781|NCT04077866|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103427782|NCT04077866|Alkylating Agents|alkylating agents|mesh-ancestor
103427783|NCT04077866|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103427784|NCT04077866|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103440902|NCT05371093|Prednisone|prednisone|mesh-list
103440903|NCT05371093|Cyclophosphamide|cyclophosphamide|mesh-list
103440904|NCT05371093|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103440905|NCT05371093|Rituximab|rituximab|mesh-list
103440906|NCT05371093|Doxorubicin|doxorubicin|mesh-list
103440907|NCT05371093|Fludarabine|fludarabine|mesh-list
103440908|NCT05371093|Vincristine|vincristine|mesh-list
103440909|NCT05371093|Lenalidomide|lenalidomide|mesh-list
103440910|NCT05371093|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103440911|NCT05371093|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103440912|NCT05371093|Immunologic Factors|immunologic factors|mesh-ancestor
103440913|NCT05371093|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103440914|NCT05371093|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103440915|NCT05371093|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103440916|NCT05371093|Alkylating Agents|alkylating agents|mesh-ancestor
103440917|NCT05371093|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103440918|NCT05371093|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103440919|NCT05371093|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103440920|NCT05371093|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103440921|NCT05371093|Antibiotics, Antineoplastic|antibiotics, antineoplastic|mesh-ancestor
103440922|NCT05371093|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
103440923|NCT05371093|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
103440924|NCT05371093|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103440925|NCT05371093|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
103440926|NCT05371093|Glucocorticoids|glucocorticoids|mesh-ancestor
103440927|NCT05371093|Hormones|hormones|mesh-ancestor
103440928|NCT05371093|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
103440929|NCT05371093|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
103440930|NCT05371093|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
103440931|NCT05371093|Tubulin Modulators|tubulin modulators|mesh-ancestor
103440932|NCT05371093|Antimitotic Agents|antimitotic agents|mesh-ancestor
103440933|NCT05371093|Mitosis Modulators|mitosis modulators|mesh-ancestor
103440934|NCT05371093|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
103440935|NCT05371093|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
103440936|NCT05371093|Growth Substances|growth substances|mesh-ancestor
103440937|NCT05371093|Growth Inhibitors|growth inhibitors|mesh-ancestor
103440939|NCT05364424|Obinutuzumab|obinutuzumab|mesh-list
103440940|NCT05364424|Carboplatin|carboplatin|mesh-list
103440941|NCT05364424|Etoposide|etoposide|mesh-list
103440942|NCT05364424|Ifosfamide|ifosfamide|mesh-list
103440943|NCT05364424|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103440944|NCT05364424|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103440945|NCT05364424|Immunologic Factors|immunologic factors|mesh-ancestor
103440946|NCT05364424|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103440947|NCT05364424|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103440948|NCT05364424|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
103440949|NCT05364424|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
103440950|NCT05364424|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
103440951|NCT05364424|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103440952|NCT05364424|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103440953|NCT05364424|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103440954|NCT05364424|Alkylating Agents|alkylating agents|mesh-ancestor
103441243|NCT04989803|Cyclophosphamide|cyclophosphamide|mesh-list
103441244|NCT04989803|Fludarabine|fludarabine|mesh-list
103441245|NCT04989803|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103441246|NCT04989803|Immunologic Factors|immunologic factors|mesh-ancestor
103441247|NCT04989803|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103441248|NCT04989803|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103441249|NCT04989803|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103441250|NCT04989803|Alkylating Agents|alkylating agents|mesh-ancestor
103441251|NCT04989803|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103441252|NCT04989803|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103441253|NCT04989803|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103441318|NCT04897321|Cyclophosphamide|cyclophosphamide|mesh-list
103441319|NCT04897321|Fludarabine|fludarabine|mesh-list
103441320|NCT04897321|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103441321|NCT04897321|Immunologic Factors|immunologic factors|mesh-ancestor
103441322|NCT04897321|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103441323|NCT04897321|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103441324|NCT04897321|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103441325|NCT04897321|Alkylating Agents|alkylating agents|mesh-ancestor
103441326|NCT04897321|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103441327|NCT04897321|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103441328|NCT04897321|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103441719|NCT04196413|Cyclophosphamide|cyclophosphamide|mesh-list
103441720|NCT04196413|Fludarabine|fludarabine|mesh-list
103441721|NCT04196413|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103441722|NCT04196413|Immunologic Factors|immunologic factors|mesh-ancestor
103441723|NCT04196413|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103441724|NCT04196413|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103441725|NCT04196413|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103441726|NCT04196413|Alkylating Agents|alkylating agents|mesh-ancestor
103441727|NCT04196413|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103441728|NCT04196413|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103441729|NCT04196413|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103252516|NCT03573700|Cyclophosphamide|cyclophosphamide|mesh-list
103252517|NCT03573700|Fludarabine|fludarabine|mesh-list
103252518|NCT03573700|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103252519|NCT03573700|Immunologic Factors|immunologic factors|mesh-ancestor
103252520|NCT03573700|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103252521|NCT03573700|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103252522|NCT03573700|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103252523|NCT03573700|Alkylating Agents|alkylating agents|mesh-ancestor
103252524|NCT03573700|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103252525|NCT03573700|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103252526|NCT03573700|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102763595|NCT03117751|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103256408|NCT04119024|Cyclophosphamide|cyclophosphamide|mesh-list
103256409|NCT04119024|Fludarabine|fludarabine|mesh-list
103256410|NCT04119024|Fludarabine phosphate|fludarabine phosphate|mesh-list
103256411|NCT04119024|Interleukin-2|interleukin-2|mesh-list
103256412|NCT04119024|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103256413|NCT04119024|Immunologic Factors|immunologic factors|mesh-ancestor
103256414|NCT04119024|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103256415|NCT04119024|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103256416|NCT04119024|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103256417|NCT04119024|Alkylating Agents|alkylating agents|mesh-ancestor
103256418|NCT04119024|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103256419|NCT04119024|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103256420|NCT04119024|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103256421|NCT04119024|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103256422|NCT04119024|Antimetabolites|antimetabolites|mesh-ancestor
103256423|NCT04119024|Analgesics, Non-Narcotic|analgesics, non-narcotic|mesh-ancestor
103256425|NCT04119024|Sensory System Agents|sensory system agents|mesh-ancestor
103256426|NCT04119024|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103263307|NCT04696731|Cyclophosphamide|cyclophosphamide|mesh-list
103263308|NCT04696731|Fludarabine|fludarabine|mesh-list
103263309|NCT04696731|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103263310|NCT04696731|Immunologic Factors|immunologic factors|mesh-ancestor
103263311|NCT04696731|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103263312|NCT04696731|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103263313|NCT04696731|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103263314|NCT04696731|Alkylating Agents|alkylating agents|mesh-ancestor
103263315|NCT04696731|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103263316|NCT04696731|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103263317|NCT04696731|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103264528|NCT05590221|Cyclophosphamide|cyclophosphamide|mesh-list
103264530|NCT05590221|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103264531|NCT05590221|Immunologic Factors|immunologic factors|mesh-ancestor
103264532|NCT05590221|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103264533|NCT05590221|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103264534|NCT05590221|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103264535|NCT05590221|Alkylating Agents|alkylating agents|mesh-ancestor
103264536|NCT05590221|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103264537|NCT05590221|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103264538|NCT05590221|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103272235|NCT03958656|Cyclophosphamide|cyclophosphamide|mesh-list
103272236|NCT03958656|Fludarabine|fludarabine|mesh-list
103272237|NCT03958656|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103272238|NCT03958656|Immunologic Factors|immunologic factors|mesh-ancestor
103272239|NCT03958656|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103272240|NCT03958656|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103272241|NCT03958656|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103272242|NCT03958656|Alkylating Agents|alkylating agents|mesh-ancestor
103272243|NCT03958656|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103272244|NCT03958656|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103272245|NCT03958656|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103280322|NCT04082910|Infliximab|infliximab|mesh-list
103280323|NCT04082910|Etanercept|etanercept|mesh-list
103280324|NCT04082910|Metoprolol|metoprolol|mesh-list
103280325|NCT04082910|Tumor Necrosis Factor Inhibitors|tumor necrosis factor inhibitors|mesh-ancestor
103280326|NCT04082910|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
103280327|NCT04082910|Dermatologic Agents|dermatologic agents|mesh-ancestor
103280328|NCT04082910|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
103280329|NCT04082910|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103280330|NCT04082910|Anti-Inflammatory Agents, Non-Steroidal|anti-inflammatory agents, non-steroidal|mesh-ancestor
103280331|NCT04082910|Analgesics, Non-Narcotic|analgesics, non-narcotic|mesh-ancestor
103280332|NCT04082910|Analgesics|analgesics|mesh-ancestor
103280333|NCT04082910|Sensory System Agents|sensory system agents|mesh-ancestor
103280334|NCT04082910|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103280335|NCT04082910|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103280336|NCT04082910|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103280337|NCT04082910|Immunologic Factors|immunologic factors|mesh-ancestor
103280338|NCT04082910|Anti-Arrhythmia Agents|anti-arrhythmia agents|mesh-ancestor
103280339|NCT04082910|Antihypertensive Agents|antihypertensive agents|mesh-ancestor
103280340|NCT04082910|Sympatholytics|sympatholytics|mesh-ancestor
103280341|NCT04082910|Autonomic Agents|autonomic agents|mesh-ancestor
103280342|NCT04082910|Adrenergic beta-1 Receptor Antagonists|adrenergic beta-1 receptor antagonists|mesh-ancestor
103280343|NCT04082910|Adrenergic beta-Antagonists|adrenergic beta-antagonists|mesh-ancestor
103280344|NCT04082910|Adrenergic Antagonists|adrenergic antagonists|mesh-ancestor
103280345|NCT04082910|Adrenergic Agents|adrenergic agents|mesh-ancestor
103280346|NCT04082910|Neurotransmitter Agents|neurotransmitter agents|mesh-ancestor
103280347|NCT04082910|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103055913|NCT04205838|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102999366|NCT04665063|Cyclophosphamide|cyclophosphamide|mesh-list
102999367|NCT04665063|Fludarabine|fludarabine|mesh-list
102999368|NCT04665063|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102999369|NCT04665063|Immunologic Factors|immunologic factors|mesh-ancestor
102999370|NCT04665063|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102999371|NCT04665063|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102999372|NCT04665063|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102999373|NCT04665063|Alkylating Agents|alkylating agents|mesh-ancestor
102999374|NCT04665063|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102999375|NCT04665063|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102999376|NCT04665063|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103002168|NCT03455972|Immunomodulating Agents|immunomodulating agents|mesh-list
103002169|NCT03455972|Immunologic Factors|immunologic factors|mesh-ancestor
103002170|NCT03455972|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103002843|NCT04626765|Cyclophosphamide|cyclophosphamide|mesh-list
103002844|NCT04626765|Fludarabine|fludarabine|mesh-list
103002845|NCT04626765|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103002846|NCT04626765|Immunologic Factors|immunologic factors|mesh-ancestor
103002847|NCT04626765|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103002848|NCT04626765|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103002849|NCT04626765|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103002850|NCT04626765|Alkylating Agents|alkylating agents|mesh-ancestor
103002851|NCT04626765|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103002852|NCT04626765|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103002853|NCT04626765|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103002854|NCT04626726|Cyclophosphamide|cyclophosphamide|mesh-list
103002855|NCT04626726|Fludarabine|fludarabine|mesh-list
103002856|NCT04626726|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103002857|NCT04626726|Immunologic Factors|immunologic factors|mesh-ancestor
103002858|NCT04626726|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103002859|NCT04626726|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103002860|NCT04626726|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103002861|NCT04626726|Alkylating Agents|alkylating agents|mesh-ancestor
103002862|NCT04626726|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103002863|NCT04626726|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103002864|NCT04626726|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103004037|NCT04890236|Tisagenlecleucel|tisagenlecleucel|mesh-list
103004038|NCT04890236|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103004039|NCT04890236|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103005987|NCT04603872|Dasatinib|dasatinib|mesh-list
103005988|NCT04603872|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103005989|NCT04603872|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
103005990|NCT04603872|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103005991|NCT04603872|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103006036|NCT04626752|Cyclophosphamide|cyclophosphamide|mesh-list
103006037|NCT04626752|Fludarabine|fludarabine|mesh-list
103006038|NCT04626752|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103006039|NCT04626752|Immunologic Factors|immunologic factors|mesh-ancestor
103006040|NCT04626752|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103006041|NCT04626752|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103006042|NCT04626752|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103006043|NCT04626752|Alkylating Agents|alkylating agents|mesh-ancestor
103006044|NCT04626752|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103006045|NCT04626752|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103006046|NCT04626752|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103013355|NCT04991948|Pembrolizumab|pembrolizumab|mesh-list
103013356|NCT04991948|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103013357|NCT04991948|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103013358|NCT04991948|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103013359|NCT04991948|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103014011|NCT04539444|Tislelizumab|tislelizumab|mesh-list
103014012|NCT04539444|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-list
103014013|NCT04539444|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103014014|NCT04539444|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103014015|NCT04539444|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103015384|NCT04553393|Decitabine|decitabine|mesh-list
103015385|NCT04553393|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103015386|NCT04553393|Antimetabolites|antimetabolites|mesh-ancestor
103015387|NCT04553393|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103015388|NCT04553393|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103015389|NCT04553393|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
103029070|NCT01218867|Aldesleukin|aldesleukin|mesh-list
103029071|NCT01218867|Cyclophosphamide|cyclophosphamide|mesh-list
103029072|NCT01218867|Fludarabine|fludarabine|mesh-list
103029073|NCT01218867|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103029074|NCT01218867|Immunologic Factors|immunologic factors|mesh-ancestor
103029075|NCT01218867|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103029076|NCT01218867|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103029077|NCT01218867|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103029078|NCT01218867|Alkylating Agents|alkylating agents|mesh-ancestor
103029079|NCT01218867|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103029080|NCT01218867|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103029081|NCT01218867|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103029082|NCT01218867|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
103029083|NCT01218867|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
103029084|NCT01218867|Antiviral Agents|antiviral agents|mesh-ancestor
103029085|NCT01218867|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103031525|NCT02792114|Cyclophosphamide|cyclophosphamide|mesh-list
103031526|NCT02792114|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103031527|NCT02792114|Immunologic Factors|immunologic factors|mesh-ancestor
103031528|NCT02792114|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103031529|NCT02792114|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103031530|NCT02792114|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103031531|NCT02792114|Alkylating Agents|alkylating agents|mesh-ancestor
103031532|NCT02792114|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103031533|NCT02792114|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103031534|NCT02792114|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103035039|NCT04264039|Fludarabine|fludarabine|mesh-list
103035040|NCT04264039|Cyclophosphamide|cyclophosphamide|mesh-list
103035042|NCT04264039|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103035043|NCT04264039|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103035044|NCT04264039|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103035045|NCT04264039|Immunologic Factors|immunologic factors|mesh-ancestor
103035046|NCT04264039|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103035047|NCT04264039|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103035048|NCT04264039|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103035049|NCT04264039|Alkylating Agents|alkylating agents|mesh-ancestor
103035050|NCT04264039|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103035537|NCT04844866|Rituximab|rituximab|mesh-list
103035538|NCT04844866|Gemcitabine|gemcitabine|mesh-list
103035539|NCT04844866|Oxaliplatin|oxaliplatin|mesh-list
103035540|NCT04844866|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103035541|NCT04844866|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
103035542|NCT04844866|Polatuzumab vedotin|polatuzumab vedotin|mesh-list
103035543|NCT04844866|Immunoconjugates|immunoconjugates|mesh-list
103035544|NCT04844866|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103035545|NCT04844866|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103035546|NCT04844866|Immunologic Factors|immunologic factors|mesh-ancestor
103035547|NCT04844866|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103035548|NCT04844866|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103035549|NCT04844866|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103035550|NCT04844866|Antimetabolites|antimetabolites|mesh-ancestor
103035551|NCT04844866|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103035552|NCT04844866|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103035553|NCT04844866|Alkylating Agents|alkylating agents|mesh-ancestor
103035617|NCT04483778|Pembrolizumab|pembrolizumab|mesh-list
103035618|NCT04483778|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103035619|NCT04483778|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103035620|NCT04483778|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103035621|NCT04483778|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103036842|NCT05625594|Cyclophosphamide|cyclophosphamide|mesh-list
103036843|NCT05625594|Fludarabine|fludarabine|mesh-list
103036844|NCT05625594|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103036845|NCT05625594|Immunologic Factors|immunologic factors|mesh-ancestor
103036846|NCT05625594|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103036847|NCT05625594|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103036848|NCT05625594|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103036849|NCT05625594|Alkylating Agents|alkylating agents|mesh-ancestor
103036850|NCT05625594|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103036851|NCT05625594|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103036852|NCT05625594|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103481156|NCT03799913|Cyclophosphamide|cyclophosphamide|mesh-list
103481157|NCT03799913|Fludarabine|fludarabine|mesh-list
103481158|NCT03799913|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103481159|NCT03799913|Immunologic Factors|immunologic factors|mesh-ancestor
103481160|NCT03799913|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103481161|NCT03799913|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103481162|NCT03799913|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103481163|NCT03799913|Alkylating Agents|alkylating agents|mesh-ancestor
103481164|NCT03799913|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103481165|NCT03799913|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103481166|NCT03799913|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103035041|NCT04264039|Melphalan|melphalan|mesh-list
103487853|NCT02456350|Cyclophosphamide|cyclophosphamide|mesh-list
103487854|NCT02456350|Fludarabine|fludarabine|mesh-list
103487855|NCT02456350|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103487856|NCT02456350|Immunologic Factors|immunologic factors|mesh-ancestor
103487857|NCT02456350|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103487858|NCT02456350|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103487859|NCT02456350|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103487860|NCT02456350|Alkylating Agents|alkylating agents|mesh-ancestor
103487861|NCT02456350|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103487862|NCT02456350|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103487863|NCT02456350|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103492832|NCT05008575|Fludarabine|fludarabine|mesh-list
103492833|NCT05008575|Cyclophosphamide|cyclophosphamide|mesh-list
103492834|NCT05008575|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103492835|NCT05008575|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103492836|NCT05008575|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103492837|NCT05008575|Immunologic Factors|immunologic factors|mesh-ancestor
103492838|NCT05008575|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103492839|NCT05008575|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103492840|NCT05008575|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103492841|NCT05008575|Alkylating Agents|alkylating agents|mesh-ancestor
103492842|NCT05008575|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103493703|NCT03361748|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
103493704|NCT03361748|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103493705|NCT03361748|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103496910|NCT04440436|Cyclophosphamide|cyclophosphamide|mesh-list
103496911|NCT04440436|Fludarabine|fludarabine|mesh-list
103496912|NCT04440436|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103496913|NCT04440436|Immunologic Factors|immunologic factors|mesh-ancestor
103496914|NCT04440436|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103496915|NCT04440436|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103496916|NCT04440436|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103496917|NCT04440436|Alkylating Agents|alkylating agents|mesh-ancestor
103496918|NCT04440436|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103496919|NCT04440436|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103496920|NCT04440436|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103500960|NCT03726515|Pembrolizumab|pembrolizumab|mesh-list
103500961|NCT03726515|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103500962|NCT03726515|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103500963|NCT03726515|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
103500964|NCT03726515|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103504986|NCT04385173|Temozolomide|temozolomide|mesh-list
103504987|NCT04385173|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103504988|NCT04385173|Alkylating Agents|alkylating agents|mesh-ancestor
103504989|NCT04385173|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103504990|NCT04385173|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103505470|NCT03706547|Cyclophosphamide|cyclophosphamide|mesh-list
103505471|NCT03706547|Fludarabine|fludarabine|mesh-list
103505472|NCT03706547|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103505473|NCT03706547|Immunologic Factors|immunologic factors|mesh-ancestor
103505474|NCT03706547|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103505475|NCT03706547|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103505476|NCT03706547|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103505477|NCT03706547|Alkylating Agents|alkylating agents|mesh-ancestor
103505478|NCT03706547|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103505479|NCT03706547|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103505480|NCT03706547|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103510908|NCT03318861|Cyclophosphamide|cyclophosphamide|mesh-list
103510909|NCT03318861|Fludarabine|fludarabine|mesh-list
103510910|NCT03318861|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103510911|NCT03318861|Immunologic Factors|immunologic factors|mesh-ancestor
103510912|NCT03318861|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103510913|NCT03318861|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103510914|NCT03318861|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103510915|NCT03318861|Alkylating Agents|alkylating agents|mesh-ancestor
103510916|NCT03318861|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103510917|NCT03318861|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103510918|NCT03318861|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103519757|NCT05665725|Siltuximab|siltuximab|mesh-list
103519758|NCT05665725|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
103519759|NCT05665725|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103519760|NCT05665725|Immunologic Factors|immunologic factors|mesh-ancestor
103519761|NCT05665725|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103522712|NCT04083495|Cyclophosphamide|cyclophosphamide|mesh-list
103522713|NCT04083495|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103522714|NCT04083495|Fludarabine|fludarabine|mesh-list
103522715|NCT04083495|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103522716|NCT04083495|Immunologic Factors|immunologic factors|mesh-ancestor
103522717|NCT04083495|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103522718|NCT04083495|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103522719|NCT04083495|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103522720|NCT04083495|Alkylating Agents|alkylating agents|mesh-ancestor
103522721|NCT04083495|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103522722|NCT04083495|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103522723|NCT04083495|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103522842|NCT03873805|Vidarabine|vidarabine|mesh-list
103522843|NCT03873805|Cyclophosphamide|cyclophosphamide|mesh-list
103522844|NCT03873805|Fludarabine|fludarabine|mesh-list
103522845|NCT03873805|Fludarabine phosphate|fludarabine phosphate|mesh-list
103522846|NCT03873805|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103522847|NCT03873805|Immunologic Factors|immunologic factors|mesh-ancestor
103522848|NCT03873805|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103522849|NCT03873805|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103522850|NCT03873805|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103522851|NCT03873805|Alkylating Agents|alkylating agents|mesh-ancestor
103522852|NCT03873805|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103522853|NCT03873805|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103522854|NCT03873805|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103522855|NCT03873805|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103522856|NCT03873805|Antimetabolites|antimetabolites|mesh-ancestor
103522857|NCT03873805|Antiviral Agents|antiviral agents|mesh-ancestor
103522858|NCT03873805|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103523787|NCT05370547|Cyclophosphamide|cyclophosphamide|mesh-list
103523788|NCT05370547|Fludarabine|fludarabine|mesh-list
103523789|NCT05370547|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103523790|NCT05370547|Immunologic Factors|immunologic factors|mesh-ancestor
103523791|NCT05370547|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103523792|NCT05370547|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103523793|NCT05370547|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103523794|NCT05370547|Alkylating Agents|alkylating agents|mesh-ancestor
103523795|NCT05370547|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103523796|NCT05370547|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103523797|NCT05370547|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103524033|NCT02134262|Cyclophosphamide|cyclophosphamide|mesh-list
103524034|NCT02134262|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
103524035|NCT02134262|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103524036|NCT02134262|Immunologic Factors|immunologic factors|mesh-ancestor
103524037|NCT02134262|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103524038|NCT02134262|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103524039|NCT02134262|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103524040|NCT02134262|Alkylating Agents|alkylating agents|mesh-ancestor
103524041|NCT02134262|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103524042|NCT02134262|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103524043|NCT02134262|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103524589|NCT03579888|Cyclophosphamide|cyclophosphamide|mesh-list
103524590|NCT03579888|Fludarabine|fludarabine|mesh-list
103524591|NCT03579888|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103524592|NCT03579888|Immunologic Factors|immunologic factors|mesh-ancestor
103524593|NCT03579888|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103524594|NCT03579888|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103524595|NCT03579888|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103524596|NCT03579888|Alkylating Agents|alkylating agents|mesh-ancestor
103524597|NCT03579888|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103524598|NCT03579888|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103524599|NCT03579888|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103526614|NCT03181126|Venetoclax|venetoclax|mesh-list
103526615|NCT03181126|Navitoclax|navitoclax|mesh-list
103526616|NCT03181126|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103077187|NCT02685670|Cyclophosphamide|cyclophosphamide|mesh-list
103529650|NCT05020392|Vidarabine|vidarabine|mesh-list
103529651|NCT05020392|Fludarabine|fludarabine|mesh-list
103529652|NCT05020392|Fludarabine phosphate|fludarabine phosphate|mesh-list
103529653|NCT05020392|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103529654|NCT05020392|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103529655|NCT05020392|Antimetabolites|antimetabolites|mesh-ancestor
103529656|NCT05020392|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103529657|NCT05020392|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103529658|NCT05020392|Immunologic Factors|immunologic factors|mesh-ancestor
103529659|NCT05020392|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103529660|NCT05020392|Antiviral Agents|antiviral agents|mesh-ancestor
103529661|NCT05020392|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103529711|NCT04881240|Cyclophosphamide|cyclophosphamide|mesh-list
103529712|NCT04881240|Fludarabine|fludarabine|mesh-list
103529713|NCT04881240|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103529715|NCT04881240|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103529716|NCT04881240|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103529717|NCT04881240|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103529718|NCT04881240|Alkylating Agents|alkylating agents|mesh-ancestor
103529719|NCT04881240|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103529720|NCT04881240|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103529721|NCT04881240|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103535173|NCT03674463|Immunomodulating Agents|immunomodulating agents|mesh-list
103535174|NCT03674463|Immunologic Factors|immunologic factors|mesh-ancestor
103535175|NCT03674463|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103537168|NCT03559764|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
103537169|NCT03559764|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103537170|NCT03559764|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103264529|NCT05590221|Fludarabine|fludarabine|mesh-list
103547907|NCT04173988|Cyclophosphamide|cyclophosphamide|mesh-list
103547908|NCT04173988|Fludarabine|fludarabine|mesh-list
103547909|NCT04173988|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103547910|NCT04173988|Immunologic Factors|immunologic factors|mesh-ancestor
103547911|NCT04173988|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103547912|NCT04173988|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103547913|NCT04173988|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103547914|NCT04173988|Alkylating Agents|alkylating agents|mesh-ancestor
103547915|NCT04173988|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103547916|NCT04173988|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103547917|NCT04173988|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103550556|NCT02932956|Cyclophosphamide|cyclophosphamide|mesh-list
103550557|NCT02932956|Fludarabine|fludarabine|mesh-list
103550558|NCT02932956|Fludarabine phosphate|fludarabine phosphate|mesh-list
103550559|NCT02932956|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103550560|NCT02932956|Immunologic Factors|immunologic factors|mesh-ancestor
103550561|NCT02932956|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103550562|NCT02932956|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103550563|NCT02932956|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103550564|NCT02932956|Alkylating Agents|alkylating agents|mesh-ancestor
103550565|NCT02932956|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103550566|NCT02932956|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103550567|NCT02932956|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103550568|NCT02932956|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103550569|NCT02932956|Antimetabolites|antimetabolites|mesh-ancestor
102891693|NCT04514029|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102891694|NCT04514029|Glucocorticoids|glucocorticoids|mesh-ancestor
102891695|NCT04514029|Hormones|hormones|mesh-ancestor
103357069|NCT05631912|Cyclophosphamide|cyclophosphamide|mesh-list
103357070|NCT05631912|Fludarabine|fludarabine|mesh-list
103357071|NCT05631912|Fludarabine phosphate|fludarabine phosphate|mesh-list
103357072|NCT05631912|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103357073|NCT05631912|Immunologic Factors|immunologic factors|mesh-ancestor
103357074|NCT05631912|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103357075|NCT05631912|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103357076|NCT05631912|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103357077|NCT05631912|Alkylating Agents|alkylating agents|mesh-ancestor
103357078|NCT05631912|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103357079|NCT05631912|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103357080|NCT05631912|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103357081|NCT05631912|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103357082|NCT05631912|Antimetabolites|antimetabolites|mesh-ancestor
103358077|NCT04539366|Cyclophosphamide|cyclophosphamide|mesh-list
103358078|NCT04539366|Fludarabine|fludarabine|mesh-list
103358079|NCT04539366|Fludarabine phosphate|fludarabine phosphate|mesh-list
103358080|NCT04539366|Immunologic Factors|immunologic factors|mesh-ancestor
103358081|NCT04539366|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103358082|NCT04539366|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103358083|NCT04539366|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103358084|NCT04539366|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103358085|NCT04539366|Alkylating Agents|alkylating agents|mesh-ancestor
103358086|NCT04539366|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103358087|NCT04539366|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103358088|NCT04539366|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103358089|NCT04539366|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103358090|NCT04539366|Antimetabolites|antimetabolites|mesh-ancestor
103037927|NCT00840853|Acetaminophen|acetaminophen|mesh-list
103037928|NCT00840853|Diphenhydramine|diphenhydramine|mesh-list
103037929|NCT00840853|Analgesics, Non-Narcotic|analgesics, non-narcotic|mesh-ancestor
103037930|NCT00840853|Analgesics|analgesics|mesh-ancestor
103037931|NCT00840853|Sensory System Agents|sensory system agents|mesh-ancestor
103037932|NCT00840853|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
103037933|NCT00840853|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103037934|NCT00840853|Antipyretics|antipyretics|mesh-ancestor
103037935|NCT00840853|Sleep Aids, Pharmaceutical|sleep aids, pharmaceutical|mesh-ancestor
103037936|NCT00840853|Hypnotics and Sedatives|hypnotics and sedatives|mesh-ancestor
103037937|NCT00840853|Central Nervous System Depressants|central nervous system depressants|mesh-ancestor
103037938|NCT00840853|Anesthetics, Local|anesthetics, local|mesh-ancestor
103037939|NCT00840853|Anesthetics|anesthetics|mesh-ancestor
103037940|NCT00840853|Antiemetics|antiemetics|mesh-ancestor
103037941|NCT00840853|Autonomic Agents|autonomic agents|mesh-ancestor
103037942|NCT00840853|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
103037943|NCT00840853|Histamine H1 Antagonists|histamine h1 antagonists|mesh-ancestor
103037944|NCT00840853|Histamine Antagonists|histamine antagonists|mesh-ancestor
103037945|NCT00840853|Histamine Agents|histamine agents|mesh-ancestor
103037946|NCT00840853|Neurotransmitter Agents|neurotransmitter agents|mesh-ancestor
103037947|NCT00840853|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103037948|NCT00840853|Anti-Allergic Agents|anti-allergic agents|mesh-ancestor
103044910|NCT05654077|Cyclophosphamide|cyclophosphamide|mesh-list
103044911|NCT05654077|Fludarabine|fludarabine|mesh-list
103044912|NCT05654077|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103044913|NCT05654077|Immunologic Factors|immunologic factors|mesh-ancestor
103044914|NCT05654077|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103044915|NCT05654077|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103044916|NCT05654077|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103044917|NCT05654077|Alkylating Agents|alkylating agents|mesh-ancestor
103044918|NCT05654077|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103044919|NCT05654077|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103044920|NCT05654077|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103046847|NCT04975555|Siltuximab|siltuximab|mesh-list
103046848|NCT04975555|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103052046|NCT05323201|Cyclophosphamide|cyclophosphamide|mesh-list
103052047|NCT05323201|Fludarabine|fludarabine|mesh-list
103052048|NCT05323201|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103052049|NCT05323201|Immunologic Factors|immunologic factors|mesh-ancestor
103052050|NCT05323201|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103052051|NCT05323201|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103052052|NCT05323201|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103052053|NCT05323201|Alkylating Agents|alkylating agents|mesh-ancestor
103052054|NCT05323201|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103052055|NCT05323201|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103052056|NCT05323201|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103054095|NCT04264078|Fludarabine|fludarabine|mesh-list
103054096|NCT04264078|Cyclophosphamide|cyclophosphamide|mesh-list
103054097|NCT04264078|Melphalan|melphalan|mesh-list
103054098|NCT04264078|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103054099|NCT04264078|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103054100|NCT04264078|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103054101|NCT04264078|Immunologic Factors|immunologic factors|mesh-ancestor
103054102|NCT04264078|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103054103|NCT04264078|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103054104|NCT04264078|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103054105|NCT04264078|Alkylating Agents|alkylating agents|mesh-ancestor
103054106|NCT04264078|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103055895|NCT04205838|Vidarabine|vidarabine|mesh-list
103055896|NCT04205838|Cyclophosphamide|cyclophosphamide|mesh-list
103055897|NCT04205838|Fludarabine|fludarabine|mesh-list
103055898|NCT04205838|Fludarabine phosphate|fludarabine phosphate|mesh-list
103055899|NCT04205838|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103055900|NCT04205838|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
103055901|NCT04205838|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103055902|NCT04205838|Immunologic Factors|immunologic factors|mesh-ancestor
103055903|NCT04205838|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103055904|NCT04205838|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103055905|NCT04205838|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103055906|NCT04205838|Alkylating Agents|alkylating agents|mesh-ancestor
103055907|NCT04205838|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103055908|NCT04205838|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103055909|NCT04205838|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103055910|NCT04205838|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103055911|NCT04205838|Antimetabolites|antimetabolites|mesh-ancestor
103055912|NCT04205838|Antiviral Agents|antiviral agents|mesh-ancestor
103055914|NCT04205838|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102916569|NCT04653493|Fludarabine|fludarabine|mesh-list
102929946|NCT04610125|Cyclophosphamide|cyclophosphamide|mesh-list
103061492|NCT00902044|Cyclophosphamide|cyclophosphamide|mesh-list
103061493|NCT00902044|Fludarabine|fludarabine|mesh-list
103061494|NCT00902044|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103061495|NCT00902044|Immunologic Factors|immunologic factors|mesh-ancestor
103061496|NCT00902044|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103061497|NCT00902044|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103061498|NCT00902044|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103061499|NCT00902044|Alkylating Agents|alkylating agents|mesh-ancestor
103061500|NCT00902044|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103061501|NCT00902044|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103061502|NCT00902044|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102399327|NCT04268706|Fludarabine|fludarabine|mesh-list
103083549|NCT03624036|Cyclophosphamide|cyclophosphamide|mesh-list
103083550|NCT03624036|Fludarabine|fludarabine|mesh-list
103083551|NCT03624036|Brexucabtagene autoleucel|brexucabtagene autoleucel|mesh-list
103083552|NCT03624036|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103083553|NCT03624036|Immunologic Factors|immunologic factors|mesh-ancestor
103083554|NCT03624036|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103083555|NCT03624036|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103083556|NCT03624036|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103083557|NCT03624036|Alkylating Agents|alkylating agents|mesh-ancestor
103083558|NCT03624036|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103083559|NCT03624036|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103083560|NCT03624036|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103083561|NCT03624036|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102409397|NCT04287660|Hormones|hormones|mesh-ancestor
103093381|NCT02876978|Cyclophosphamide|cyclophosphamide|mesh-list
103093382|NCT02876978|Fludarabine|fludarabine|mesh-list
103093383|NCT02876978|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103093384|NCT02876978|Immunologic Factors|immunologic factors|mesh-ancestor
103093385|NCT02876978|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103093386|NCT02876978|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103093387|NCT02876978|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103093388|NCT02876978|Alkylating Agents|alkylating agents|mesh-ancestor
103093389|NCT02876978|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103093390|NCT02876978|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103093391|NCT02876978|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103093450|NCT04303520|Cyclophosphamide|cyclophosphamide|mesh-list
103093451|NCT04303520|Fludarabine|fludarabine|mesh-list
103093452|NCT04303520|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103093453|NCT04303520|Immunologic Factors|immunologic factors|mesh-ancestor
103093454|NCT04303520|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103093455|NCT04303520|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103093456|NCT04303520|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103093457|NCT04303520|Alkylating Agents|alkylating agents|mesh-ancestor
103093458|NCT04303520|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103093459|NCT04303520|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103093460|NCT04303520|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102863698|NCT05035407|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
102553648|NCT03430011|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
102553649|NCT03430011|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103106301|NCT02575261|Immunomodulating Agents|immunomodulating agents|mesh-list
103106302|NCT02575261|Immunologic Factors|immunologic factors|mesh-ancestor
103106303|NCT02575261|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103108340|NCT04093648|Cyclophosphamide|cyclophosphamide|mesh-list
103108341|NCT04093648|Fludarabine|fludarabine|mesh-list
103108342|NCT04093648|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103108343|NCT04093648|Immunologic Factors|immunologic factors|mesh-ancestor
103108344|NCT04093648|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103108345|NCT04093648|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103108346|NCT04093648|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103108347|NCT04093648|Alkylating Agents|alkylating agents|mesh-ancestor
103108348|NCT04093648|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103108349|NCT04093648|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103108350|NCT04093648|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103123730|NCT03601078|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103123731|NCT03601078|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103130104|NCT02844062|Cyclophosphamide|cyclophosphamide|mesh-list
103130105|NCT02844062|Fludarabine|fludarabine|mesh-list
103130106|NCT02844062|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103130107|NCT02844062|Immunologic Factors|immunologic factors|mesh-ancestor
103130108|NCT02844062|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103130109|NCT02844062|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103130110|NCT02844062|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103130111|NCT02844062|Alkylating Agents|alkylating agents|mesh-ancestor
103130112|NCT02844062|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103130113|NCT02844062|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103130114|NCT02844062|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103141124|NCT05659628|Tislelizumab|tislelizumab|mesh-list
103141125|NCT05659628|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103141126|NCT05659628|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103141447|NCT05379569|Cyclophosphamide|cyclophosphamide|mesh-list
103141448|NCT05379569|Fludarabine|fludarabine|mesh-list
103141449|NCT05379569|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103141450|NCT05379569|Immunologic Factors|immunologic factors|mesh-ancestor
103141451|NCT05379569|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103141452|NCT05379569|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103141453|NCT05379569|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103141454|NCT05379569|Alkylating Agents|alkylating agents|mesh-ancestor
103141455|NCT05379569|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103141456|NCT05379569|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103141457|NCT05379569|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103142509|NCT05639972|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103142510|NCT05639972|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
103142511|NCT05639972|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
103142512|NCT05639972|Antiviral Agents|antiviral agents|mesh-ancestor
103142513|NCT05639972|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102367519|NCT05164770|Hormones|hormones|mesh-ancestor
103153388|NCT03666000|Fludarabine|fludarabine|mesh-list
103153389|NCT03666000|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103153390|NCT03666000|Immunologic Factors|immunologic factors|mesh-ancestor
103153391|NCT03666000|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103153392|NCT03666000|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103153393|NCT03666000|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103153394|NCT03666000|Alkylating Agents|alkylating agents|mesh-ancestor
103153395|NCT03666000|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103153396|NCT03666000|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103153397|NCT03666000|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103189834|NCT04160195|Cyclophosphamide|cyclophosphamide|mesh-list
103189835|NCT04160195|Fludarabine|fludarabine|mesh-list
103189836|NCT04160195|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103189837|NCT04160195|Immunologic Factors|immunologic factors|mesh-ancestor
103189838|NCT04160195|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103189839|NCT04160195|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103189840|NCT04160195|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103189841|NCT04160195|Alkylating Agents|alkylating agents|mesh-ancestor
103189842|NCT04160195|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103189843|NCT04160195|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103189844|NCT04160195|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102514159|NCT05070156|Vaccines|vaccines|mesh-list
103077188|NCT02685670|Fludarabine|fludarabine|mesh-list
103077189|NCT02685670|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103077190|NCT02685670|Immunologic Factors|immunologic factors|mesh-ancestor
103077191|NCT02685670|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103077192|NCT02685670|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103077193|NCT02685670|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103077194|NCT02685670|Alkylating Agents|alkylating agents|mesh-ancestor
103077195|NCT02685670|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103077196|NCT02685670|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103077197|NCT02685670|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103337858|NCT05371132|Deferoxamine|deferoxamine|mesh-list
103337859|NCT05371132|Siderophores|siderophores|mesh-ancestor
103337860|NCT05371132|Iron Chelating Agents|iron chelating agents|mesh-ancestor
103337861|NCT05371132|Chelating Agents|chelating agents|mesh-ancestor
103337862|NCT05371132|Sequestering Agents|sequestering agents|mesh-ancestor
103337863|NCT05371132|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103343227|NCT03879382|Cyclophosphamide|cyclophosphamide|mesh-list
103343228|NCT03879382|Fludarabine|fludarabine|mesh-list
103343229|NCT03879382|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103343230|NCT03879382|Immunologic Factors|immunologic factors|mesh-ancestor
103343231|NCT03879382|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103343232|NCT03879382|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103343233|NCT03879382|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103343234|NCT03879382|Alkylating Agents|alkylating agents|mesh-ancestor
103343235|NCT03879382|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103343236|NCT03879382|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103343237|NCT03879382|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103348098|NCT05495464|Cyclophosphamide|cyclophosphamide|mesh-list
103348099|NCT05495464|Rituximab|rituximab|mesh-list
103348100|NCT05495464|Fludarabine|fludarabine|mesh-list
103348101|NCT05495464|Fludarabine phosphate|fludarabine phosphate|mesh-list
103348102|NCT05495464|Acalabrutinib|acalabrutinib|mesh-list
103348103|NCT05495464|Brexucabtagene autoleucel|brexucabtagene autoleucel|mesh-list
103348104|NCT05495464|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103348105|NCT05495464|Immunologic Factors|immunologic factors|mesh-ancestor
103348106|NCT05495464|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103348107|NCT05495464|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103348108|NCT05495464|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103348109|NCT05495464|Alkylating Agents|alkylating agents|mesh-ancestor
103348110|NCT05495464|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103348111|NCT05495464|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103348112|NCT05495464|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103348113|NCT05495464|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103348114|NCT05495464|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
103348115|NCT05495464|Antimetabolites|antimetabolites|mesh-ancestor
103364786|NCT03943472|Cyclophosphamide|cyclophosphamide|mesh-list
103364787|NCT03943472|Fludarabine|fludarabine|mesh-list
103364788|NCT03943472|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
103364789|NCT03943472|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103364790|NCT03943472|Immunologic Factors|immunologic factors|mesh-ancestor
103364791|NCT03943472|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103364792|NCT03943472|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103364793|NCT03943472|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103364794|NCT03943472|Alkylating Agents|alkylating agents|mesh-ancestor
103364795|NCT03943472|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103364796|NCT03943472|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103364797|NCT03943472|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103364798|NCT03943472|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103365610|NCT03937544|Cyclophosphamide|cyclophosphamide|mesh-list
103365611|NCT03937544|Fludarabine|fludarabine|mesh-list
103365612|NCT03937544|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103365613|NCT03937544|Immunologic Factors|immunologic factors|mesh-ancestor
103365614|NCT03937544|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103365615|NCT03937544|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103365616|NCT03937544|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103365617|NCT03937544|Alkylating Agents|alkylating agents|mesh-ancestor
103365618|NCT03937544|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103365619|NCT03937544|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103365620|NCT03937544|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103372435|NCT03448978|Cyclophosphamide|cyclophosphamide|mesh-list
103372436|NCT03448978|Fludarabine|fludarabine|mesh-list
103372437|NCT03448978|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103372438|NCT03448978|Immunologic Factors|immunologic factors|mesh-ancestor
103372439|NCT03448978|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103372440|NCT03448978|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103372441|NCT03448978|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103372442|NCT03448978|Alkylating Agents|alkylating agents|mesh-ancestor
103372443|NCT03448978|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103372444|NCT03448978|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103372445|NCT03448978|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103385396|NCT05359211|Cyclophosphamide|cyclophosphamide|mesh-list
103385397|NCT05359211|Fludarabine|fludarabine|mesh-list
103385398|NCT05359211|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103385399|NCT05359211|Immunologic Factors|immunologic factors|mesh-ancestor
103385400|NCT05359211|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103385401|NCT05359211|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103385402|NCT05359211|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103385403|NCT05359211|Alkylating Agents|alkylating agents|mesh-ancestor
103385404|NCT05359211|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103385405|NCT05359211|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103385406|NCT05359211|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102454567|NCT04767308|Cyclophosphamide|cyclophosphamide|mesh-list
103223538|NCT04561557|Cyclophosphamide|cyclophosphamide|mesh-list
103223539|NCT04561557|Fludarabine|fludarabine|mesh-list
103223540|NCT04561557|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103223541|NCT04561557|Immunologic Factors|immunologic factors|mesh-ancestor
103223542|NCT04561557|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103223543|NCT04561557|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103223544|NCT04561557|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103223545|NCT04561557|Alkylating Agents|alkylating agents|mesh-ancestor
103223546|NCT04561557|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103223547|NCT04561557|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103223548|NCT04561557|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103229995|NCT04037566|Cyclophosphamide|cyclophosphamide|mesh-list
103229996|NCT04037566|Fludarabine|fludarabine|mesh-list
103229997|NCT04037566|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103229998|NCT04037566|Immunologic Factors|immunologic factors|mesh-ancestor
103229999|NCT04037566|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103230000|NCT04037566|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103230001|NCT04037566|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103230002|NCT04037566|Alkylating Agents|alkylating agents|mesh-ancestor
103230003|NCT04037566|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103230004|NCT04037566|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103230005|NCT04037566|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102666549|NCT04148430|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
102666550|NCT04148430|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102666551|NCT03467256|Cytarabine|cytarabine|mesh-list
102666552|NCT03467256|Dexamethasone|dexamethasone|mesh-list
102666553|NCT03467256|Cyclophosphamide|cyclophosphamide|mesh-list
102666554|NCT03467256|Fludarabine|fludarabine|mesh-list
102666555|NCT03467256|Etoposide|etoposide|mesh-list
102666556|NCT03467256|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102666557|NCT03467256|Immunologic Factors|immunologic factors|mesh-ancestor
102666558|NCT03467256|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102666559|NCT03467256|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102666560|NCT03467256|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102666561|NCT03467256|Alkylating Agents|alkylating agents|mesh-ancestor
102666562|NCT03467256|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102666563|NCT03467256|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102666564|NCT03467256|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102666565|NCT03467256|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102666566|NCT03467256|Antiemetics|antiemetics|mesh-ancestor
102666567|NCT03467256|Autonomic Agents|autonomic agents|mesh-ancestor
102666568|NCT03467256|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102666569|NCT03467256|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102666570|NCT03467256|Glucocorticoids|glucocorticoids|mesh-ancestor
102666571|NCT03467256|Hormones|hormones|mesh-ancestor
102666572|NCT03467256|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102666573|NCT03467256|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102666574|NCT03467256|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102666575|NCT03467256|Antimetabolites|antimetabolites|mesh-ancestor
102666576|NCT03467256|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102666577|NCT03467256|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102666578|NCT03467256|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102666579|NCT03467256|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102666580|NCT03467256|Antiviral Agents|antiviral agents|mesh-ancestor
102666581|NCT03467256|Anti-Infective Agents|anti-infective agents|mesh-ancestor
103111960|NCT05077527|Cyclophosphamide|cyclophosphamide|mesh-list
103111961|NCT05077527|Fludarabine|fludarabine|mesh-list
103111962|NCT05077527|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
103111963|NCT05077527|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103111964|NCT05077527|Immunologic Factors|immunologic factors|mesh-ancestor
103111965|NCT05077527|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103111966|NCT05077527|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103111967|NCT05077527|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103111968|NCT05077527|Alkylating Agents|alkylating agents|mesh-ancestor
103111969|NCT05077527|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103111970|NCT05077527|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103111971|NCT05077527|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103111972|NCT05077527|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103123729|NCT03601078|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
102672606|NCT05052528|Cyclophosphamide|cyclophosphamide|mesh-list
102672607|NCT05052528|Rituximab|rituximab|mesh-list
102672608|NCT05052528|Fludarabine|fludarabine|mesh-list
102672609|NCT05052528|Fludarabine phosphate|fludarabine phosphate|mesh-list
102672610|NCT05052528|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-list
102672611|NCT05052528|Antibodies|antibodies|mesh-list
102672612|NCT05052528|Immunoglobulins|immunoglobulins|mesh-list
102672613|NCT05052528|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
102672614|NCT05052528|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102672615|NCT05052528|Immunologic Factors|immunologic factors|mesh-ancestor
102672616|NCT05052528|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102672617|NCT05052528|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102672618|NCT05052528|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102672619|NCT05052528|Alkylating Agents|alkylating agents|mesh-ancestor
102672620|NCT05052528|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102672621|NCT05052528|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102672622|NCT05052528|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102672623|NCT05052528|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102672624|NCT05052528|Antimetabolites|antimetabolites|mesh-ancestor
102443662|NCT04121273|Immunologic Factors|immunologic factors|mesh-ancestor
102680990|NCT05418088|Cyclophosphamide|cyclophosphamide|mesh-list
102680991|NCT05418088|Fludarabine|fludarabine|mesh-list
102680992|NCT05418088|Fludarabine phosphate|fludarabine phosphate|mesh-list
102680993|NCT05418088|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102680994|NCT05418088|Immunologic Factors|immunologic factors|mesh-ancestor
102680995|NCT05418088|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102680996|NCT05418088|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102680997|NCT05418088|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102680998|NCT05418088|Alkylating Agents|alkylating agents|mesh-ancestor
102680999|NCT05418088|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102681000|NCT05418088|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102681001|NCT05418088|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102681002|NCT05418088|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102681003|NCT05418088|Antimetabolites|antimetabolites|mesh-ancestor
102685991|NCT03761056|Cyclophosphamide|cyclophosphamide|mesh-list
102685992|NCT03761056|Fludarabine|fludarabine|mesh-list
102685993|NCT03761056|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102685994|NCT03761056|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102685995|NCT03761056|Immunologic Factors|immunologic factors|mesh-ancestor
102685996|NCT03761056|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102685997|NCT03761056|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102685998|NCT03761056|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102685999|NCT03761056|Alkylating Agents|alkylating agents|mesh-ancestor
102686000|NCT03761056|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102686001|NCT03761056|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102686002|NCT03761056|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102686003|NCT03761056|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103142508|NCT05639972|Aldesleukin|aldesleukin|mesh-list
103153387|NCT03666000|Cyclophosphamide|cyclophosphamide|mesh-list
103155763|NCT02723942|Immunomodulating Agents|immunomodulating agents|mesh-list
103155764|NCT02723942|Immunologic Factors|immunologic factors|mesh-ancestor
103155765|NCT02723942|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102704105|NCT04205409|Nivolumab|nivolumab|mesh-list
102704106|NCT04205409|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102704107|NCT04205409|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102704108|NCT04205409|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102704109|NCT04205409|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102724855|NCT04359784|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
102724856|NCT04359784|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102479410|NCT04381741|Antibodies|antibodies|mesh-list
102750703|NCT05225363|Cyclophosphamide|cyclophosphamide|mesh-list
102750704|NCT05225363|Fludarabine|fludarabine|mesh-list
102750705|NCT05225363|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102750706|NCT05225363|Immunologic Factors|immunologic factors|mesh-ancestor
102750707|NCT05225363|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102750708|NCT05225363|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102750709|NCT05225363|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102750710|NCT05225363|Alkylating Agents|alkylating agents|mesh-ancestor
102750711|NCT05225363|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102750712|NCT05225363|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102750713|NCT05225363|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102751071|NCT04074330|Rituximab|rituximab|mesh-list
102751072|NCT04074330|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102751073|NCT04074330|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102751074|NCT04074330|Immunologic Factors|immunologic factors|mesh-ancestor
102751075|NCT04074330|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102751076|NCT04074330|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102364237|NCT03030976|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102485658|NCT03030001|Antibodies|antibodies|mesh-list
102763566|NCT03117751|Cytarabine|cytarabine|mesh-list
102763567|NCT03117751|Dexamethasone|dexamethasone|mesh-list
102763568|NCT03117751|Prednisone|prednisone|mesh-list
102763569|NCT03117751|Prednisolone|prednisolone|mesh-list
102763570|NCT03117751|Cyclophosphamide|cyclophosphamide|mesh-list
102763571|NCT03117751|Doxorubicin|doxorubicin|mesh-list
102763572|NCT03117751|Methotrexate|methotrexate|mesh-list
102763573|NCT03117751|Etoposide|etoposide|mesh-list
102763574|NCT03117751|Etoposide phosphate|etoposide phosphate|mesh-list
102763575|NCT03117751|Vincristine|vincristine|mesh-list
102763576|NCT03117751|Bortezomib|bortezomib|mesh-list
102763577|NCT03117751|Daunorubicin|daunorubicin|mesh-list
102763578|NCT03117751|Asparaginase|asparaginase|mesh-list
102763579|NCT03117751|Dasatinib|dasatinib|mesh-list
102763580|NCT03117751|Mercaptopurine|mercaptopurine|mesh-list
102763581|NCT03117751|Vorinostat|vorinostat|mesh-list
102763582|NCT03117751|Idarubicin|idarubicin|mesh-list
102763583|NCT03117751|Clofarabine|clofarabine|mesh-list
102763584|NCT03117751|Pegaspargase|pegaspargase|mesh-list
102763585|NCT03117751|Thioguanine|thioguanine|mesh-list
102763586|NCT03117751|Blinatumomab|blinatumomab|mesh-list
102763587|NCT03117751|Asparaginase erwinia chrysanthemi, recombinant-rywn|asparaginase erwinia chrysanthemi, recombinant-rywn|mesh-list
102763588|NCT03117751|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102763589|NCT03117751|Immunologic Factors|immunologic factors|mesh-ancestor
102763590|NCT03117751|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102763591|NCT03117751|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102763592|NCT03117751|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102763593|NCT03117751|Alkylating Agents|alkylating agents|mesh-ancestor
102763600|NCT03117751|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102763601|NCT03117751|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102763602|NCT03117751|Glucocorticoids|glucocorticoids|mesh-ancestor
102763604|NCT03117751|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102763605|NCT03117751|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102763606|NCT03117751|Antibiotics, Antineoplastic|antibiotics, antineoplastic|mesh-ancestor
102763607|NCT03117751|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102763608|NCT03117751|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102763609|NCT03117751|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102763610|NCT03117751|Abortifacient Agents, Nonsteroidal|abortifacient agents, nonsteroidal|mesh-ancestor
102763611|NCT03117751|Abortifacient Agents|abortifacient agents|mesh-ancestor
102763612|NCT03117751|Reproductive Control Agents|reproductive control agents|mesh-ancestor
102763613|NCT03117751|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102763614|NCT03117751|Antimetabolites|antimetabolites|mesh-ancestor
102763615|NCT03117751|Dermatologic Agents|dermatologic agents|mesh-ancestor
102763616|NCT03117751|Folic Acid Antagonists|folic acid antagonists|mesh-ancestor
102763617|NCT03117751|Nucleic Acid Synthesis Inhibitors|nucleic acid synthesis inhibitors|mesh-ancestor
102763618|NCT03117751|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102763619|NCT03117751|Antiviral Agents|antiviral agents|mesh-ancestor
102763620|NCT03117751|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102763621|NCT03117751|Tubulin Modulators|tubulin modulators|mesh-ancestor
102763622|NCT03117751|Antimitotic Agents|antimitotic agents|mesh-ancestor
102763623|NCT03117751|Mitosis Modulators|mitosis modulators|mesh-ancestor
102763624|NCT03117751|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
102763625|NCT03117751|Histone Deacetylase Inhibitors|histone deacetylase inhibitors|mesh-ancestor
102763818|NCT01840566|Cytarabine|cytarabine|mesh-list
102763819|NCT01840566|Etoposide|etoposide|mesh-list
102763820|NCT01840566|Melphalan|melphalan|mesh-list
102763821|NCT01840566|Carmustine|carmustine|mesh-list
102763822|NCT01840566|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102763823|NCT01840566|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102763824|NCT01840566|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102763825|NCT01840566|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102763826|NCT01840566|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102763827|NCT01840566|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102763828|NCT01840566|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102763829|NCT01840566|Antimetabolites|antimetabolites|mesh-ancestor
102763830|NCT01840566|Antiviral Agents|antiviral agents|mesh-ancestor
102763831|NCT01840566|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102763832|NCT01840566|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102763833|NCT01840566|Immunologic Factors|immunologic factors|mesh-ancestor
102763834|NCT01840566|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102763835|NCT01840566|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102763836|NCT01840566|Alkylating Agents|alkylating agents|mesh-ancestor
102763837|NCT01840566|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103205709|NCT04094766|Immunomodulating Agents|immunomodulating agents|mesh-list
103205710|NCT04094766|Immunologic Factors|immunologic factors|mesh-ancestor
103205711|NCT04094766|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102911846|NCT04133636|Glucocorticoids|glucocorticoids|mesh-ancestor
103176793|NCT05260957|Polatuzumab vedotin|polatuzumab vedotin|mesh-list
103176794|NCT05260957|Immunoconjugates|immunoconjugates|mesh-ancestor
103176795|NCT05260957|Immunologic Factors|immunologic factors|mesh-ancestor
103176796|NCT05260957|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102681417|NCT03098355|Interleukin-2|interleukin-2|mesh-list
102681418|NCT03098355|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102681419|NCT03098355|Analgesics, Non-Narcotic|analgesics, non-narcotic|mesh-ancestor
102681420|NCT03098355|Analgesics|analgesics|mesh-ancestor
102681421|NCT03098355|Sensory System Agents|sensory system agents|mesh-ancestor
102681422|NCT03098355|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102681423|NCT03098355|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102366659|NCT03602157|Fludarabine|fludarabine|mesh-list
102367499|NCT05164770|Prednisone|prednisone|mesh-list
102367505|NCT05164770|Etoposide|etoposide|mesh-list
103359291|NCT02414269|Cyclophosphamide|cyclophosphamide|mesh-list
103359292|NCT02414269|Pembrolizumab|pembrolizumab|mesh-list
103359293|NCT02414269|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
103359294|NCT02414269|Immunologic Factors|immunologic factors|mesh-ancestor
103359295|NCT02414269|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
103359296|NCT02414269|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
103359297|NCT02414269|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
103359298|NCT02414269|Alkylating Agents|alkylating agents|mesh-ancestor
103359299|NCT02414269|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
103359300|NCT02414269|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
103359301|NCT02414269|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
103359302|NCT02414269|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
103359303|NCT02414269|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102929950|NCT04610125|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102929951|NCT04610125|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102929952|NCT04610125|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102929953|NCT04610125|Alkylating Agents|alkylating agents|mesh-ancestor
102993653|NCT04530565|Mesna|mesna|mesh-list
102763594|NCT03117751|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102763596|NCT03117751|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102763597|NCT03117751|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102763598|NCT03117751|Antiemetics|antiemetics|mesh-ancestor
102763599|NCT03117751|Autonomic Agents|autonomic agents|mesh-ancestor
102763603|NCT03117751|Hormones|hormones|mesh-ancestor
102653533|NCT05322330|Fludarabine|fludarabine|mesh-list
102891687|NCT04514029|Simvastatin|simvastatin|mesh-list
102891686|NCT04514029|Dexamethasone|dexamethasone|mesh-list
102891688|NCT04514029|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102891689|NCT04514029|Antiemetics|antiemetics|mesh-ancestor
102891690|NCT04514029|Autonomic Agents|autonomic agents|mesh-ancestor
102891691|NCT04514029|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102891692|NCT04514029|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102891696|NCT04514029|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102891697|NCT04514029|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102891698|NCT04514029|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102891699|NCT04514029|Anticholesteremic Agents|anticholesteremic agents|mesh-ancestor
102891700|NCT04514029|Hypolipidemic Agents|hypolipidemic agents|mesh-ancestor
102891701|NCT04514029|Antimetabolites|antimetabolites|mesh-ancestor
102891702|NCT04514029|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102891703|NCT04514029|Lipid Regulating Agents|lipid regulating agents|mesh-ancestor
102891704|NCT04514029|Hydroxymethylglutaryl-CoA Reductase Inhibitors|hydroxymethylglutaryl-coa reductase inhibitors|mesh-ancestor
102891705|NCT04514029|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102907785|NCT05075603|Tisagenlecleucel|tisagenlecleucel|mesh-list
102907786|NCT05075603|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102907787|NCT05075603|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102907788|NCT05075603|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102902205|NCT02937844|Cyclophosphamide|cyclophosphamide|mesh-list
102902206|NCT02937844|Fludarabine|fludarabine|mesh-list
102902207|NCT02937844|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102902208|NCT02937844|Immunologic Factors|immunologic factors|mesh-ancestor
102902209|NCT02937844|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102902210|NCT02937844|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102902211|NCT02937844|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102902212|NCT02937844|Alkylating Agents|alkylating agents|mesh-ancestor
102902213|NCT02937844|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102902214|NCT02937844|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102902215|NCT02937844|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102911261|NCT04923893|Dexamethasone|dexamethasone|mesh-list
102911262|NCT04923893|Cyclophosphamide|cyclophosphamide|mesh-list
102911263|NCT04923893|Fludarabine|fludarabine|mesh-list
102911264|NCT04923893|Lenalidomide|lenalidomide|mesh-list
102911265|NCT04923893|Bortezomib|bortezomib|mesh-list
102911266|NCT04923893|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102911267|NCT04923893|Immunologic Factors|immunologic factors|mesh-ancestor
102911268|NCT04923893|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102911269|NCT04923893|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102911270|NCT04923893|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102911271|NCT04923893|Alkylating Agents|alkylating agents|mesh-ancestor
102911272|NCT04923893|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102911273|NCT04923893|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102911274|NCT04923893|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102911275|NCT04923893|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102911276|NCT04923893|Antiemetics|antiemetics|mesh-ancestor
102911277|NCT04923893|Autonomic Agents|autonomic agents|mesh-ancestor
102911278|NCT04923893|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102911279|NCT04923893|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102911280|NCT04923893|Glucocorticoids|glucocorticoids|mesh-ancestor
102911281|NCT04923893|Hormones|hormones|mesh-ancestor
102911282|NCT04923893|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102911283|NCT04923893|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102911284|NCT04923893|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
102911285|NCT04923893|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
102911286|NCT04923893|Growth Substances|growth substances|mesh-ancestor
102911287|NCT04923893|Growth Inhibitors|growth inhibitors|mesh-ancestor
102911765|NCT04181827|Dexamethasone|dexamethasone|mesh-list
102911766|NCT04181827|Bortezomib|bortezomib|mesh-list
102911767|NCT04181827|Daratumumab|daratumumab|mesh-list
102911768|NCT04181827|Pomalidomide|pomalidomide|mesh-list
102911769|NCT04181827|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102911770|NCT04181827|Antiemetics|antiemetics|mesh-ancestor
102911771|NCT04181827|Autonomic Agents|autonomic agents|mesh-ancestor
102911772|NCT04181827|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102911773|NCT04181827|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102911774|NCT04181827|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102911775|NCT04181827|Glucocorticoids|glucocorticoids|mesh-ancestor
102911776|NCT04181827|Hormones|hormones|mesh-ancestor
102911777|NCT04181827|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102911778|NCT04181827|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102911779|NCT04181827|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102911780|NCT04181827|Immunologic Factors|immunologic factors|mesh-ancestor
102911781|NCT04181827|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
102911782|NCT04181827|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
102911783|NCT04181827|Growth Substances|growth substances|mesh-ancestor
102911784|NCT04181827|Growth Inhibitors|growth inhibitors|mesh-ancestor
102911836|NCT04133636|Dexamethasone|dexamethasone|mesh-list
102911837|NCT04133636|Lenalidomide|lenalidomide|mesh-list
102911838|NCT04133636|Bortezomib|bortezomib|mesh-list
102911839|NCT04133636|Daratumumab|daratumumab|mesh-list
102911840|NCT04133636|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102911841|NCT04133636|Antiemetics|antiemetics|mesh-ancestor
102911842|NCT04133636|Autonomic Agents|autonomic agents|mesh-ancestor
102911843|NCT04133636|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102911844|NCT04133636|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102911845|NCT04133636|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102911847|NCT04133636|Hormones|hormones|mesh-ancestor
102911848|NCT04133636|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102911849|NCT04133636|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102911850|NCT04133636|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102911851|NCT04133636|Immunologic Factors|immunologic factors|mesh-ancestor
102911852|NCT04133636|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
102911853|NCT04133636|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
102911854|NCT04133636|Growth Substances|growth substances|mesh-ancestor
102911855|NCT04133636|Growth Inhibitors|growth inhibitors|mesh-ancestor
102912738|NCT01430390|Cyclophosphamide|cyclophosphamide|mesh-list
102912739|NCT01430390|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102912740|NCT01430390|Immunologic Factors|immunologic factors|mesh-ancestor
102912741|NCT01430390|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102912742|NCT01430390|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102912743|NCT01430390|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102912744|NCT01430390|Alkylating Agents|alkylating agents|mesh-ancestor
102912745|NCT01430390|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102912746|NCT01430390|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102912747|NCT01430390|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102916568|NCT04653493|Cyclophosphamide|cyclophosphamide|mesh-list
102916570|NCT04653493|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102916571|NCT04653493|Immunologic Factors|immunologic factors|mesh-ancestor
102916572|NCT04653493|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102916573|NCT04653493|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102916574|NCT04653493|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102916575|NCT04653493|Alkylating Agents|alkylating agents|mesh-ancestor
102916576|NCT04653493|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102916577|NCT04653493|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102916578|NCT04653493|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102807981|NCT05576181|Cyclophosphamide|cyclophosphamide|mesh-list
102807982|NCT05576181|Fludarabine|fludarabine|mesh-list
102807983|NCT05576181|Etoposide|etoposide|mesh-list
102807984|NCT05576181|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102807985|NCT05576181|Immunologic Factors|immunologic factors|mesh-ancestor
102807986|NCT05576181|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102807987|NCT05576181|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102807988|NCT05576181|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102807989|NCT05576181|Alkylating Agents|alkylating agents|mesh-ancestor
102807990|NCT05576181|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102807991|NCT05576181|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102807992|NCT05576181|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102807993|NCT05576181|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102807994|NCT05576181|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102807995|NCT05576181|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102807996|NCT05576181|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102808049|NCT05640713|Cyclophosphamide|cyclophosphamide|mesh-list
102808050|NCT05640713|Fludarabine|fludarabine|mesh-list
102808051|NCT05640713|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102808052|NCT05640713|Immunologic Factors|immunologic factors|mesh-ancestor
102808053|NCT05640713|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102808054|NCT05640713|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102808055|NCT05640713|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102808056|NCT05640713|Alkylating Agents|alkylating agents|mesh-ancestor
102808057|NCT05640713|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102808058|NCT05640713|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102808059|NCT05640713|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102815510|NCT01818323|Immunomodulating Agents|immunomodulating agents|mesh-list
102815511|NCT01818323|Immunologic Factors|immunologic factors|mesh-ancestor
102815512|NCT01818323|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102822590|NCT05020444|Cyclophosphamide|cyclophosphamide|mesh-list
102822591|NCT05020444|Fludarabine|fludarabine|mesh-list
102822592|NCT05020444|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102822593|NCT05020444|Immunologic Factors|immunologic factors|mesh-ancestor
102822594|NCT05020444|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102822595|NCT05020444|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102822596|NCT05020444|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102822597|NCT05020444|Alkylating Agents|alkylating agents|mesh-ancestor
102822598|NCT05020444|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102822599|NCT05020444|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102822600|NCT05020444|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102938962|NCT04532281|Carbamide Peroxide|carbamide peroxide|mesh-list
102938963|NCT04532281|Anti-Infective Agents, Local|anti-infective agents, local|mesh-ancestor
102938964|NCT04532281|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102653451|NCT05665062|Cyclophosphamide|cyclophosphamide|mesh-list
102653452|NCT05665062|Fludarabine|fludarabine|mesh-list
102653453|NCT05665062|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102653454|NCT05665062|Immunologic Factors|immunologic factors|mesh-ancestor
102653455|NCT05665062|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102653456|NCT05665062|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102653457|NCT05665062|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102653458|NCT05665062|Alkylating Agents|alkylating agents|mesh-ancestor
102653459|NCT05665062|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102653460|NCT05665062|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102653461|NCT05665062|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102653532|NCT05322330|Cyclophosphamide|cyclophosphamide|mesh-list
102653534|NCT05322330|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102653535|NCT05322330|Immunologic Factors|immunologic factors|mesh-ancestor
102653536|NCT05322330|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102653537|NCT05322330|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102653538|NCT05322330|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102653539|NCT05322330|Alkylating Agents|alkylating agents|mesh-ancestor
102653540|NCT05322330|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102653541|NCT05322330|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102653542|NCT05322330|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102834641|NCT04727008|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
102834642|NCT04727008|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102834643|NCT04727008|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102372308|NCT03126864|Immunologic Factors|immunologic factors|mesh-ancestor
102531395|NCT03602612|Cyclophosphamide|cyclophosphamide|mesh-list
102862871|NCT05442515|Cyclophosphamide|cyclophosphamide|mesh-list
102862872|NCT05442515|Fludarabine|fludarabine|mesh-list
102862873|NCT05442515|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102862874|NCT05442515|Immunologic Factors|immunologic factors|mesh-ancestor
102862875|NCT05442515|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102862876|NCT05442515|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102862877|NCT05442515|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102862878|NCT05442515|Alkylating Agents|alkylating agents|mesh-ancestor
102862879|NCT05442515|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102862880|NCT05442515|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102862881|NCT05442515|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102862970|NCT05400109|Cyclophosphamide|cyclophosphamide|mesh-list
102862971|NCT05400109|Fludarabine|fludarabine|mesh-list
102862972|NCT05400109|Fludarabine phosphate|fludarabine phosphate|mesh-list
102862973|NCT05400109|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102862974|NCT05400109|Immunologic Factors|immunologic factors|mesh-ancestor
102862975|NCT05400109|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102862976|NCT05400109|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102862977|NCT05400109|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102862978|NCT05400109|Alkylating Agents|alkylating agents|mesh-ancestor
102862979|NCT05400109|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102862980|NCT05400109|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102862981|NCT05400109|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102862982|NCT05400109|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102862983|NCT05400109|Antimetabolites|antimetabolites|mesh-ancestor
102863686|NCT05035407|Aldesleukin|aldesleukin|mesh-list
102863687|NCT05035407|Cyclophosphamide|cyclophosphamide|mesh-list
102863688|NCT05035407|Fludarabine|fludarabine|mesh-list
102863689|NCT05035407|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102863690|NCT05035407|Immunologic Factors|immunologic factors|mesh-ancestor
102863691|NCT05035407|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102863692|NCT05035407|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102863693|NCT05035407|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102863694|NCT05035407|Alkylating Agents|alkylating agents|mesh-ancestor
102863695|NCT05035407|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102863696|NCT05035407|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102863697|NCT05035407|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102863699|NCT05035407|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
102863700|NCT05035407|Antiviral Agents|antiviral agents|mesh-ancestor
102863701|NCT05035407|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102863733|NCT05003895|Cyclophosphamide|cyclophosphamide|mesh-list
102863734|NCT05003895|Fludarabine|fludarabine|mesh-list
102863735|NCT05003895|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102863736|NCT05003895|Immunologic Factors|immunologic factors|mesh-ancestor
102863737|NCT05003895|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102863738|NCT05003895|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102863739|NCT05003895|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102863740|NCT05003895|Alkylating Agents|alkylating agents|mesh-ancestor
102863741|NCT05003895|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102863742|NCT05003895|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102863743|NCT05003895|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102864823|NCT04416984|Cyclophosphamide|cyclophosphamide|mesh-list
102864824|NCT04416984|Fludarabine|fludarabine|mesh-list
102864825|NCT04416984|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102864826|NCT04416984|Immunologic Factors|immunologic factors|mesh-ancestor
102864827|NCT04416984|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102864828|NCT04416984|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102864829|NCT04416984|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102864830|NCT04416984|Alkylating Agents|alkylating agents|mesh-ancestor
102864831|NCT04416984|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102864832|NCT04416984|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102864833|NCT04416984|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102865035|NCT04227275|Cyclophosphamide|cyclophosphamide|mesh-list
102865036|NCT04227275|Fludarabine|fludarabine|mesh-list
102865037|NCT04227275|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
102865038|NCT04227275|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102865039|NCT04227275|Immunologic Factors|immunologic factors|mesh-ancestor
102865040|NCT04227275|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102865041|NCT04227275|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102865042|NCT04227275|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102865043|NCT04227275|Alkylating Agents|alkylating agents|mesh-ancestor
102865044|NCT04227275|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102865045|NCT04227275|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102865046|NCT04227275|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102865341|NCT04029038|Cyclophosphamide|cyclophosphamide|mesh-list
102865342|NCT04029038|Fludarabine|fludarabine|mesh-list
102865343|NCT04029038|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102865344|NCT04029038|Immunologic Factors|immunologic factors|mesh-ancestor
102865345|NCT04029038|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102865346|NCT04029038|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102865347|NCT04029038|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102865348|NCT04029038|Alkylating Agents|alkylating agents|mesh-ancestor
102865349|NCT04029038|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102865350|NCT04029038|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102865351|NCT04029038|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102526228|NCT02159495|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102526229|NCT02159495|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102597368|NCT05513612|Fludarabine|fludarabine|mesh-list
102479411|NCT04381741|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
102479412|NCT04381741|Immunologic Factors|immunologic factors|mesh-ancestor
102479413|NCT04381741|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102623510|NCT04406610|Immunologic Factors|immunologic factors|mesh-ancestor
102372314|NCT03126864|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102575002|NCT03994705|Cyclophosphamide|cyclophosphamide|mesh-list
102575003|NCT03994705|Fludarabine|fludarabine|mesh-list
102575004|NCT03994705|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102575005|NCT03994705|Immunologic Factors|immunologic factors|mesh-ancestor
102575006|NCT03994705|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102575007|NCT03994705|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102575008|NCT03994705|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102575009|NCT03994705|Alkylating Agents|alkylating agents|mesh-ancestor
102575010|NCT03994705|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102575011|NCT03994705|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102575012|NCT03994705|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102577578|NCT05616468|Cyclophosphamide|cyclophosphamide|mesh-list
102577579|NCT05616468|Fludarabine|fludarabine|mesh-list
102577580|NCT05616468|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102577581|NCT05616468|Immunologic Factors|immunologic factors|mesh-ancestor
102577582|NCT05616468|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102577583|NCT05616468|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102577584|NCT05616468|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102577585|NCT05616468|Alkylating Agents|alkylating agents|mesh-ancestor
102577586|NCT05616468|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102577587|NCT05616468|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102577588|NCT05616468|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102584188|NCT02650999|Pembrolizumab|pembrolizumab|mesh-list
102584189|NCT02650999|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102584190|NCT02650999|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102584191|NCT02650999|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102584192|NCT02650999|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102586033|NCT04337606|Decitabine|decitabine|mesh-list
102586034|NCT04337606|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102586035|NCT04337606|Antimetabolites|antimetabolites|mesh-ancestor
102586036|NCT04337606|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102586037|NCT04337606|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102586038|NCT04337606|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102410082|NCT04007029|Antimetabolites|antimetabolites|mesh-ancestor
102597289|NCT05531708|Cyclophosphamide|cyclophosphamide|mesh-list
102597290|NCT05531708|Fludarabine|fludarabine|mesh-list
102597291|NCT05531708|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102597292|NCT05531708|Immunologic Factors|immunologic factors|mesh-ancestor
102597293|NCT05531708|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102597294|NCT05531708|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102597295|NCT05531708|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102597296|NCT05531708|Alkylating Agents|alkylating agents|mesh-ancestor
102597297|NCT05531708|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102597298|NCT05531708|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102597299|NCT05531708|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102597367|NCT05513612|Cyclophosphamide|cyclophosphamide|mesh-list
102597369|NCT05513612|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102597370|NCT05513612|Immunologic Factors|immunologic factors|mesh-ancestor
102597371|NCT05513612|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102597372|NCT05513612|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102597373|NCT05513612|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102597374|NCT05513612|Alkylating Agents|alkylating agents|mesh-ancestor
102597375|NCT05513612|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102597376|NCT05513612|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102597377|NCT05513612|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102409389|NCT04287660|Lenalidomide|lenalidomide|mesh-list
102346446|NCT04318678|Cyclophosphamide|cyclophosphamide|mesh-list
102346447|NCT04318678|Rituximab|rituximab|mesh-list
102453966|NCT05577000|Cyclophosphamide|cyclophosphamide|mesh-list
102359372|NCT03696784|Cyclophosphamide|cyclophosphamide|mesh-list
102359373|NCT03696784|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
102359374|NCT03696784|Fludarabine|fludarabine|mesh-list
102359375|NCT03696784|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102359376|NCT03696784|Immunologic Factors|immunologic factors|mesh-ancestor
102359377|NCT03696784|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102359378|NCT03696784|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102359379|NCT03696784|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102359380|NCT03696784|Alkylating Agents|alkylating agents|mesh-ancestor
102359381|NCT03696784|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102359382|NCT03696784|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102359383|NCT03696784|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102360417|NCT04088890|Cyclophosphamide|cyclophosphamide|mesh-list
102360418|NCT04088890|Fludarabine|fludarabine|mesh-list
102360419|NCT04088890|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102360420|NCT04088890|Immunologic Factors|immunologic factors|mesh-ancestor
102360421|NCT04088890|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102360422|NCT04088890|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102360423|NCT04088890|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102360424|NCT04088890|Alkylating Agents|alkylating agents|mesh-ancestor
102360425|NCT04088890|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102360426|NCT04088890|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102360427|NCT04088890|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102364230|NCT03030976|Cyclophosphamide|cyclophosphamide|mesh-list
102364231|NCT03030976|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102364232|NCT03030976|Immunologic Factors|immunologic factors|mesh-ancestor
102364233|NCT03030976|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102364234|NCT03030976|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102364235|NCT03030976|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102364236|NCT03030976|Alkylating Agents|alkylating agents|mesh-ancestor
102364238|NCT03030976|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102364239|NCT03030976|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102366660|NCT03602157|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
102366661|NCT03602157|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102366662|NCT03602157|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102366663|NCT03602157|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102366664|NCT03602157|Alkylating Agents|alkylating agents|mesh-ancestor
102366781|NCT03049449|Cyclophosphamide|cyclophosphamide|mesh-list
102366782|NCT03049449|Fludarabine|fludarabine|mesh-list
102366783|NCT03049449|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102366784|NCT03049449|Immunologic Factors|immunologic factors|mesh-ancestor
102366785|NCT03049449|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102366786|NCT03049449|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102366787|NCT03049449|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102366788|NCT03049449|Alkylating Agents|alkylating agents|mesh-ancestor
102366789|NCT03049449|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102366790|NCT03049449|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102366791|NCT03049449|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102367500|NCT05164770|Zanubrutinib|zanubrutinib|mesh-list
102367501|NCT05164770|Cyclophosphamide|cyclophosphamide|mesh-list
102367502|NCT05164770|Vincristine|vincristine|mesh-list
102367503|NCT05164770|Rituximab|rituximab|mesh-list
102367504|NCT05164770|Doxorubicin|doxorubicin|mesh-list
102367506|NCT05164770|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102367507|NCT05164770|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
102367508|NCT05164770|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102367509|NCT05164770|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102367510|NCT05164770|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102367511|NCT05164770|Immunologic Factors|immunologic factors|mesh-ancestor
102367512|NCT05164770|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102367513|NCT05164770|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102367514|NCT05164770|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102367515|NCT05164770|Alkylating Agents|alkylating agents|mesh-ancestor
102367516|NCT05164770|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102367517|NCT05164770|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102367518|NCT05164770|Glucocorticoids|glucocorticoids|mesh-ancestor
102367520|NCT05164770|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102367521|NCT05164770|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102367522|NCT05164770|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102367523|NCT05164770|Tubulin Modulators|tubulin modulators|mesh-ancestor
102367524|NCT05164770|Antimitotic Agents|antimitotic agents|mesh-ancestor
102367525|NCT05164770|Mitosis Modulators|mitosis modulators|mesh-ancestor
102367526|NCT05164770|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102367527|NCT05164770|Antibiotics, Antineoplastic|antibiotics, antineoplastic|mesh-ancestor
102367528|NCT05164770|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102367529|NCT05164770|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102955441|NCT04715217|Cyclophosphamide|cyclophosphamide|mesh-list
102955442|NCT04715217|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102955443|NCT04715217|Immunologic Factors|immunologic factors|mesh-ancestor
102955444|NCT04715217|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102955445|NCT04715217|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102955446|NCT04715217|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102955447|NCT04715217|Alkylating Agents|alkylating agents|mesh-ancestor
102955448|NCT04715217|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102955449|NCT04715217|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102955450|NCT04715217|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102956920|NCT04714827|Cyclophosphamide|cyclophosphamide|mesh-list
102956921|NCT04714827|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102956922|NCT04714827|Immunologic Factors|immunologic factors|mesh-ancestor
102956923|NCT04714827|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102956924|NCT04714827|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102956925|NCT04714827|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102956926|NCT04714827|Alkylating Agents|alkylating agents|mesh-ancestor
102956927|NCT04714827|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102956928|NCT04714827|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102956929|NCT04714827|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102958107|NCT04714593|Cyclophosphamide|cyclophosphamide|mesh-list
102958108|NCT04714593|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102958109|NCT04714593|Immunologic Factors|immunologic factors|mesh-ancestor
102958110|NCT04714593|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102958111|NCT04714593|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102958112|NCT04714593|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102958113|NCT04714593|Alkylating Agents|alkylating agents|mesh-ancestor
102958114|NCT04714593|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102958115|NCT04714593|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102958116|NCT04714593|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102484915|NCT02980315|Immunomodulating Agents|immunomodulating agents|mesh-list
102484916|NCT02980315|Immunologic Factors|immunologic factors|mesh-ancestor
102484917|NCT02980315|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102485659|NCT03030001|Immunologic Factors|immunologic factors|mesh-ancestor
102485660|NCT03030001|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102984387|NCT02933775|Cyclophosphamide|cyclophosphamide|mesh-list
102984388|NCT02933775|Fludarabine|fludarabine|mesh-list
102984389|NCT02933775|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102984390|NCT02933775|Immunologic Factors|immunologic factors|mesh-ancestor
102984391|NCT02933775|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102984392|NCT02933775|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102984393|NCT02933775|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102984394|NCT02933775|Alkylating Agents|alkylating agents|mesh-ancestor
102984395|NCT02933775|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102984396|NCT02933775|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102984397|NCT02933775|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102927601|NCT04666168|Cyclophosphamide|cyclophosphamide|mesh-list
102927602|NCT04666168|Fludarabine|fludarabine|mesh-list
102927603|NCT04666168|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102927604|NCT04666168|Immunologic Factors|immunologic factors|mesh-ancestor
102927605|NCT04666168|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102927606|NCT04666168|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102927607|NCT04666168|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102927608|NCT04666168|Alkylating Agents|alkylating agents|mesh-ancestor
102927609|NCT04666168|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102927610|NCT04666168|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102927611|NCT04666168|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102927679|NCT04665076|Cyclophosphamide|cyclophosphamide|mesh-list
102927680|NCT04665076|Fludarabine|fludarabine|mesh-list
102927681|NCT04665076|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102927682|NCT04665076|Immunologic Factors|immunologic factors|mesh-ancestor
102927683|NCT04665076|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102927684|NCT04665076|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102927685|NCT04665076|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102927686|NCT04665076|Alkylating Agents|alkylating agents|mesh-ancestor
102927687|NCT04665076|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102927688|NCT04665076|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102927689|NCT04665076|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102928721|NCT04626739|Cyclophosphamide|cyclophosphamide|mesh-list
102928722|NCT04626739|Fludarabine|fludarabine|mesh-list
102928723|NCT04626739|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102928724|NCT04626739|Immunologic Factors|immunologic factors|mesh-ancestor
102928725|NCT04626739|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102928726|NCT04626739|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102928727|NCT04626739|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102928728|NCT04626739|Alkylating Agents|alkylating agents|mesh-ancestor
102928729|NCT04626739|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102928730|NCT04626739|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102928731|NCT04626739|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102929947|NCT04610125|Fludarabine|fludarabine|mesh-list
102929948|NCT04610125|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102929949|NCT04610125|Immunologic Factors|immunologic factors|mesh-ancestor
102929954|NCT04610125|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102929955|NCT04610125|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102929956|NCT04610125|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102566223|NCT05000450|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102566626|NCT04855136|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
102566627|NCT04855136|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102566628|NCT04855136|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102567732|NCT04093596|Cyclophosphamide|cyclophosphamide|mesh-list
102567733|NCT04093596|Fludarabine|fludarabine|mesh-list
102567734|NCT04093596|Nirogacestat|nirogacestat|mesh-list
102567735|NCT04093596|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102567736|NCT04093596|Immunologic Factors|immunologic factors|mesh-ancestor
102567737|NCT04093596|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102567738|NCT04093596|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102567739|NCT04093596|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102567740|NCT04093596|Alkylating Agents|alkylating agents|mesh-ancestor
102567741|NCT04093596|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102567742|NCT04093596|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102567743|NCT04093596|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102567744|NCT04093596|Gamma Secretase Inhibitors and Modulators|gamma secretase inhibitors and modulators|mesh-ancestor
102567745|NCT04093596|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102992605|NCT05664217|Antithrombin III|antithrombin iii|mesh-list
102992606|NCT05664217|Antithrombins|antithrombins|mesh-list
102992607|NCT05664217|Serine Proteinase Inhibitors|serine proteinase inhibitors|mesh-ancestor
102992608|NCT05664217|Protease Inhibitors|protease inhibitors|mesh-ancestor
102992609|NCT05664217|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102992610|NCT05664217|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102992611|NCT05664217|Anticoagulants|anticoagulants|mesh-ancestor
102993547|NCT04637763|Cyclophosphamide|cyclophosphamide|mesh-list
102993548|NCT04637763|Fludarabine|fludarabine|mesh-list
102993549|NCT04637763|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102993550|NCT04637763|Immunologic Factors|immunologic factors|mesh-ancestor
102993551|NCT04637763|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102993552|NCT04637763|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102993553|NCT04637763|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102993554|NCT04637763|Alkylating Agents|alkylating agents|mesh-ancestor
102993555|NCT04637763|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102993556|NCT04637763|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102993557|NCT04637763|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102993633|NCT04530565|Cytarabine|cytarabine|mesh-list
102993634|NCT04530565|Dexamethasone|dexamethasone|mesh-list
102993635|NCT04530565|Dexamethasone acetate|dexamethasone acetate|mesh-list
102993636|NCT04530565|Prednisone|prednisone|mesh-list
102993637|NCT04530565|Cortisone|cortisone|mesh-list
102993638|NCT04530565|Cyclophosphamide|cyclophosphamide|mesh-list
102993639|NCT04530565|Doxorubicin|doxorubicin|mesh-list
102993640|NCT04530565|Liposomal doxorubicin|liposomal doxorubicin|mesh-list
102993641|NCT04530565|Methotrexate|methotrexate|mesh-list
102993642|NCT04530565|Vincristine|vincristine|mesh-list
102993643|NCT04530565|Dasatinib|dasatinib|mesh-list
102993644|NCT04530565|Blinatumomab|blinatumomab|mesh-list
102993645|NCT04530565|Ponatinib|ponatinib|mesh-list
102993646|NCT04530565|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-list
102993647|NCT04530565|Muromonab-CD3|muromonab-cd3|mesh-list
102993648|NCT04530565|Antibodies|antibodies|mesh-list
102993649|NCT04530565|Immunoglobulins|immunoglobulins|mesh-list
102993650|NCT04530565|Antibodies, Monoclonal|antibodies, monoclonal|mesh-list
102993651|NCT04530565|Antibodies, Bispecific|antibodies, bispecific|mesh-list
102993652|NCT04530565|BB 1101|bb 1101|mesh-list
102993654|NCT04530565|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102993655|NCT04530565|Immunologic Factors|immunologic factors|mesh-ancestor
102993656|NCT04530565|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102993657|NCT04530565|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102993658|NCT04530565|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102993659|NCT04530565|Alkylating Agents|alkylating agents|mesh-ancestor
102993660|NCT04530565|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102993661|NCT04530565|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102993662|NCT04530565|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102993663|NCT04530565|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102993664|NCT04530565|Antiemetics|antiemetics|mesh-ancestor
102993665|NCT04530565|Autonomic Agents|autonomic agents|mesh-ancestor
102993666|NCT04530565|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102993667|NCT04530565|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102993668|NCT04530565|Glucocorticoids|glucocorticoids|mesh-ancestor
102993669|NCT04530565|Hormones|hormones|mesh-ancestor
102993670|NCT04530565|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102993671|NCT04530565|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102993672|NCT04530565|Protease Inhibitors|protease inhibitors|mesh-ancestor
102993673|NCT04530565|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102993674|NCT04530565|Antibiotics, Antineoplastic|antibiotics, antineoplastic|mesh-ancestor
102993675|NCT04530565|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102993676|NCT04530565|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102993677|NCT04530565|Abortifacient Agents, Nonsteroidal|abortifacient agents, nonsteroidal|mesh-ancestor
102993678|NCT04530565|Abortifacient Agents|abortifacient agents|mesh-ancestor
102993679|NCT04530565|Reproductive Control Agents|reproductive control agents|mesh-ancestor
102993680|NCT04530565|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102993681|NCT04530565|Antimetabolites|antimetabolites|mesh-ancestor
102993682|NCT04530565|Dermatologic Agents|dermatologic agents|mesh-ancestor
102993683|NCT04530565|Folic Acid Antagonists|folic acid antagonists|mesh-ancestor
102993684|NCT04530565|Nucleic Acid Synthesis Inhibitors|nucleic acid synthesis inhibitors|mesh-ancestor
102993685|NCT04530565|Antiviral Agents|antiviral agents|mesh-ancestor
102993686|NCT04530565|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102993687|NCT04530565|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102993688|NCT04530565|Tubulin Modulators|tubulin modulators|mesh-ancestor
102993689|NCT04530565|Antimitotic Agents|antimitotic agents|mesh-ancestor
102993690|NCT04530565|Mitosis Modulators|mitosis modulators|mesh-ancestor
102993691|NCT04530565|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
102993692|NCT04530565|Protective Agents|protective agents|mesh-ancestor
102994568|NCT02830724|Aldesleukin|aldesleukin|mesh-list
102994569|NCT02830724|Cyclophosphamide|cyclophosphamide|mesh-list
102994570|NCT02830724|Fludarabine|fludarabine|mesh-list
102994571|NCT02830724|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102994572|NCT02830724|Immunologic Factors|immunologic factors|mesh-ancestor
102994573|NCT02830724|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102994574|NCT02830724|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102994575|NCT02830724|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102994576|NCT02830724|Alkylating Agents|alkylating agents|mesh-ancestor
102994577|NCT02830724|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102994578|NCT02830724|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102994579|NCT02830724|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102994580|NCT02830724|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
102994581|NCT02830724|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
102994582|NCT02830724|Antiviral Agents|antiviral agents|mesh-ancestor
102994583|NCT02830724|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102372304|NCT03126864|Cyclophosphamide|cyclophosphamide|mesh-list
102372305|NCT03126864|Fludarabine|fludarabine|mesh-list
102372306|NCT03126864|Fludarabine phosphate|fludarabine phosphate|mesh-list
102372307|NCT03126864|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102372309|NCT03126864|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102372310|NCT03126864|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102372311|NCT03126864|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102372312|NCT03126864|Alkylating Agents|alkylating agents|mesh-ancestor
102372313|NCT03126864|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102372315|NCT03126864|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102372316|NCT03126864|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102372317|NCT03126864|Antimetabolites|antimetabolites|mesh-ancestor
102374225|NCT01583686|Aldesleukin|aldesleukin|mesh-list
102374226|NCT01583686|Cyclophosphamide|cyclophosphamide|mesh-list
102374227|NCT01583686|Fludarabine|fludarabine|mesh-list
102374228|NCT01583686|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102374229|NCT01583686|Immunologic Factors|immunologic factors|mesh-ancestor
102374230|NCT01583686|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102374231|NCT01583686|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102374232|NCT01583686|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102374233|NCT01583686|Alkylating Agents|alkylating agents|mesh-ancestor
102374234|NCT01583686|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102374235|NCT01583686|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102374236|NCT01583686|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102374237|NCT01583686|Anti-HIV Agents|anti-hiv agents|mesh-ancestor
102374238|NCT01583686|Anti-Retroviral Agents|anti-retroviral agents|mesh-ancestor
102374239|NCT01583686|Antiviral Agents|antiviral agents|mesh-ancestor
102374240|NCT01583686|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102382810|NCT05204160|Pembrolizumab|pembrolizumab|mesh-list
102382811|NCT05204160|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102382812|NCT05204160|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102382813|NCT05204160|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102382814|NCT05204160|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102541824|NCT04499573|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102408490|NCT03110640|Cyclophosphamide|cyclophosphamide|mesh-list
102408491|NCT03110640|Fludarabine|fludarabine|mesh-list
102408492|NCT03110640|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102408493|NCT03110640|Immunologic Factors|immunologic factors|mesh-ancestor
102408494|NCT03110640|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102408495|NCT03110640|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102408496|NCT03110640|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102408497|NCT03110640|Alkylating Agents|alkylating agents|mesh-ancestor
102408498|NCT03110640|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102408499|NCT03110640|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102408500|NCT03110640|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102409387|NCT04287660|Clarithromycin|clarithromycin|mesh-list
102409405|NCT04287660|Growth Inhibitors|growth inhibitors|mesh-ancestor
102409406|NCT04287660|Anti-Bacterial Agents|anti-bacterial agents|mesh-ancestor
102409407|NCT04287660|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102409408|NCT04287660|Protein Synthesis Inhibitors|protein synthesis inhibitors|mesh-ancestor
102409409|NCT04287660|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102409410|NCT04287660|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102409411|NCT04287660|Cytochrome P-450 CYP3A Inhibitors|cytochrome p-450 cyp3a inhibitors|mesh-ancestor
102409412|NCT04287660|Cytochrome P-450 Enzyme Inhibitors|cytochrome p-450 enzyme inhibitors|mesh-ancestor
102409907|NCT04088864|Cyclophosphamide|cyclophosphamide|mesh-list
102409908|NCT04088864|Fludarabine|fludarabine|mesh-list
102409909|NCT04088864|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102409910|NCT04088864|Immunologic Factors|immunologic factors|mesh-ancestor
102409911|NCT04088864|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102409912|NCT04088864|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102409913|NCT04088864|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102409914|NCT04088864|Alkylating Agents|alkylating agents|mesh-ancestor
102409915|NCT04088864|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102410078|NCT04007029|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102410079|NCT04007029|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102410080|NCT04007029|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102410081|NCT04007029|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102399328|NCT04268706|Bendamustine Hydrochloride|bendamustine hydrochloride|mesh-list
102399329|NCT04268706|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102399330|NCT04268706|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102399331|NCT04268706|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102399332|NCT04268706|Alkylating Agents|alkylating agents|mesh-ancestor
102437816|NCT04037241|Leucovorin|leucovorin|mesh-list
102437817|NCT04037241|Paclitaxel|paclitaxel|mesh-list
102437818|NCT04037241|Gemcitabine|gemcitabine|mesh-list
102437819|NCT04037241|Capecitabine|capecitabine|mesh-list
102440011|NCT05634785|Cyclophosphamide|cyclophosphamide|mesh-list
102440012|NCT05634785|Fludarabine|fludarabine|mesh-list
102440013|NCT05634785|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102440014|NCT05634785|Immunologic Factors|immunologic factors|mesh-ancestor
102440015|NCT05634785|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102440016|NCT05634785|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102440017|NCT05634785|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102440018|NCT05634785|Alkylating Agents|alkylating agents|mesh-ancestor
102440019|NCT05634785|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102440020|NCT05634785|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102440021|NCT05634785|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102551688|NCT04003649|Ipilimumab|ipilimumab|mesh-list
102551692|NCT04003649|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102440512|NCT04995003|Pembrolizumab|pembrolizumab|mesh-list
102440513|NCT04995003|Nivolumab|nivolumab|mesh-list
102440514|NCT04995003|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-list
102440515|NCT04995003|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102440516|NCT04995003|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102440517|NCT04995003|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102440525|NCT04977024|Vaccines|vaccines|mesh-list
102440526|NCT04977024|Immunologic Factors|immunologic factors|mesh-ancestor
102440527|NCT04977024|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102441200|NCT03721068|Cyclophosphamide|cyclophosphamide|mesh-list
102441201|NCT03721068|Fludarabine|fludarabine|mesh-list
102441202|NCT03721068|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102441203|NCT03721068|Immunologic Factors|immunologic factors|mesh-ancestor
102441204|NCT03721068|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102441205|NCT03721068|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102441206|NCT03721068|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102441207|NCT03721068|Alkylating Agents|alkylating agents|mesh-ancestor
102441208|NCT03721068|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102441209|NCT03721068|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102441210|NCT03721068|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102441565|NCT03016377|Cyclophosphamide|cyclophosphamide|mesh-list
102441566|NCT03016377|Fludarabine|fludarabine|mesh-list
102441567|NCT03016377|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102441568|NCT03016377|Immunologic Factors|immunologic factors|mesh-ancestor
102441569|NCT03016377|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102441570|NCT03016377|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102441571|NCT03016377|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102441572|NCT03016377|Alkylating Agents|alkylating agents|mesh-ancestor
102441573|NCT03016377|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102441574|NCT03016377|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102441575|NCT03016377|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102409388|NCT04287660|Dexamethasone|dexamethasone|mesh-list
102409390|NCT04287660|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102409391|NCT04287660|Antiemetics|antiemetics|mesh-ancestor
102409392|NCT04287660|Autonomic Agents|autonomic agents|mesh-ancestor
102409393|NCT04287660|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102409394|NCT04287660|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102409395|NCT04287660|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102409396|NCT04287660|Glucocorticoids|glucocorticoids|mesh-ancestor
102409398|NCT04287660|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102409399|NCT04287660|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102409400|NCT04287660|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102409401|NCT04287660|Immunologic Factors|immunologic factors|mesh-ancestor
102409402|NCT04287660|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
102409403|NCT04287660|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
102409404|NCT04287660|Growth Substances|growth substances|mesh-ancestor
102409916|NCT04088864|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102409917|NCT04088864|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102410067|NCT04007029|Cyclophosphamide|cyclophosphamide|mesh-list
102410068|NCT04007029|Fludarabine|fludarabine|mesh-list
102410069|NCT04007029|Fludarabine phosphate|fludarabine phosphate|mesh-list
102410070|NCT04007029|Immunoglobulins|immunoglobulins|mesh-list
102410071|NCT04007029|Immunoglobulin G|immunoglobulin g|mesh-list
102410072|NCT04007029|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102410073|NCT04007029|Immunologic Factors|immunologic factors|mesh-ancestor
102410074|NCT04007029|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102410075|NCT04007029|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102410076|NCT04007029|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102410077|NCT04007029|Alkylating Agents|alkylating agents|mesh-ancestor
102421204|NCT05310591|Nivolumab|nivolumab|mesh-list
102421205|NCT05310591|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102421206|NCT05310591|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102421207|NCT05310591|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102421208|NCT05310591|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102448891|NCT04796688|Cyclophosphamide|cyclophosphamide|mesh-list
102448892|NCT04796688|Fludarabine|fludarabine|mesh-list
102448893|NCT04796688|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102448894|NCT04796688|Immunologic Factors|immunologic factors|mesh-ancestor
102448895|NCT04796688|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102448896|NCT04796688|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102448897|NCT04796688|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102448898|NCT04796688|Alkylating Agents|alkylating agents|mesh-ancestor
102448899|NCT04796688|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102448900|NCT04796688|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102448901|NCT04796688|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102453967|NCT05577000|Fludarabine|fludarabine|mesh-list
102453968|NCT05577000|Idecabtagene vicleucel|idecabtagene vicleucel|mesh-list
102453969|NCT05577000|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102453970|NCT05577000|Immunologic Factors|immunologic factors|mesh-ancestor
102453971|NCT05577000|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102453972|NCT05577000|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102453973|NCT05577000|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102453974|NCT05577000|Alkylating Agents|alkylating agents|mesh-ancestor
102453975|NCT05577000|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102453976|NCT05577000|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102453977|NCT05577000|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102453978|NCT05577000|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102454568|NCT04767308|Fludarabine|fludarabine|mesh-list
102454569|NCT04767308|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102454570|NCT04767308|Immunologic Factors|immunologic factors|mesh-ancestor
102454571|NCT04767308|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102454572|NCT04767308|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102454573|NCT04767308|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102454574|NCT04767308|Alkylating Agents|alkylating agents|mesh-ancestor
102454575|NCT04767308|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102454576|NCT04767308|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102461456|NCT03241940|Cyclophosphamide|cyclophosphamide|mesh-list
102461457|NCT03241940|Fludarabine|fludarabine|mesh-list
102461458|NCT03241940|Fludarabine phosphate|fludarabine phosphate|mesh-list
102461459|NCT03241940|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102461460|NCT03241940|Immunologic Factors|immunologic factors|mesh-ancestor
102461461|NCT03241940|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102461462|NCT03241940|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102461463|NCT03241940|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102461464|NCT03241940|Alkylating Agents|alkylating agents|mesh-ancestor
102461465|NCT03241940|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102461466|NCT03241940|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102461467|NCT03241940|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102461468|NCT03241940|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102461469|NCT03241940|Antimetabolites|antimetabolites|mesh-ancestor
102461470|NCT03233854|Cyclophosphamide|cyclophosphamide|mesh-list
102461471|NCT03233854|Fludarabine|fludarabine|mesh-list
102461472|NCT03233854|Fludarabine phosphate|fludarabine phosphate|mesh-list
102461473|NCT03233854|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102461474|NCT03233854|Immunologic Factors|immunologic factors|mesh-ancestor
102461475|NCT03233854|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102461476|NCT03233854|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102461477|NCT03233854|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102461478|NCT03233854|Alkylating Agents|alkylating agents|mesh-ancestor
102461479|NCT03233854|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102461480|NCT03233854|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102461481|NCT03233854|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102461482|NCT03233854|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102461483|NCT03233854|Antimetabolites|antimetabolites|mesh-ancestor
102634396|NCT05256641|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102641582|NCT04257578|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102468677|NCT03086954|Immunomodulating Agents|immunomodulating agents|mesh-list
102468678|NCT03086954|Immunologic Factors|immunologic factors|mesh-ancestor
102468679|NCT03086954|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102470202|NCT03084380|Cyclophosphamide|cyclophosphamide|mesh-list
102470203|NCT03084380|Fludarabine|fludarabine|mesh-list
102470204|NCT03084380|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102470205|NCT03084380|Immunologic Factors|immunologic factors|mesh-ancestor
102470206|NCT03084380|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102470207|NCT03084380|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102470208|NCT03084380|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102470209|NCT03084380|Alkylating Agents|alkylating agents|mesh-ancestor
102470210|NCT03084380|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102470211|NCT03084380|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102470212|NCT03084380|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102437820|NCT04037241|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102437821|NCT04037241|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102437822|NCT04037241|Tubulin Modulators|tubulin modulators|mesh-ancestor
102437823|NCT04037241|Antimitotic Agents|antimitotic agents|mesh-ancestor
102437824|NCT04037241|Mitosis Modulators|mitosis modulators|mesh-ancestor
102437825|NCT04037241|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102437826|NCT04037241|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102437827|NCT04037241|Antimetabolites|antimetabolites|mesh-ancestor
102437828|NCT04037241|Antidotes|antidotes|mesh-ancestor
102437829|NCT04037241|Protective Agents|protective agents|mesh-ancestor
102437830|NCT04037241|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102437831|NCT04037241|Vitamin B Complex|vitamin b complex|mesh-ancestor
102437832|NCT04037241|Vitamins|vitamins|mesh-ancestor
102437833|NCT04037241|Micronutrients|micronutrients|mesh-ancestor
102443661|NCT04121273|Immunomodulating Agents|immunomodulating agents|mesh-list
102443663|NCT04121273|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102504740|NCT04531046|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102504741|NCT04531046|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102504742|NCT04531046|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102454577|NCT04767308|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102514224|NCT04214886|Cyclophosphamide|cyclophosphamide|mesh-list
102514225|NCT04214886|Fludarabine|fludarabine|mesh-list
102514226|NCT04214886|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102514227|NCT04214886|Immunologic Factors|immunologic factors|mesh-ancestor
102514228|NCT04214886|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102514229|NCT04214886|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102514230|NCT04214886|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102514231|NCT04214886|Alkylating Agents|alkylating agents|mesh-ancestor
102514232|NCT04214886|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102514233|NCT04214886|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102514234|NCT04214886|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102526217|NCT02159495|Cyclophosphamide|cyclophosphamide|mesh-list
102526218|NCT02159495|Fludarabine|fludarabine|mesh-list
102526219|NCT02159495|Fludarabine phosphate|fludarabine phosphate|mesh-list
102526220|NCT02159495|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102526221|NCT02159495|Immunologic Factors|immunologic factors|mesh-ancestor
102526222|NCT02159495|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102526223|NCT02159495|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102526224|NCT02159495|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102526225|NCT02159495|Alkylating Agents|alkylating agents|mesh-ancestor
102526226|NCT02159495|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102526227|NCT02159495|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102526230|NCT02159495|Antimetabolites|antimetabolites|mesh-ancestor
102528783|NCT03013712|Immunomodulating Agents|immunomodulating agents|mesh-list
102528784|NCT03013712|Immunologic Factors|immunologic factors|mesh-ancestor
102528785|NCT03013712|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102531396|NCT03602612|Fludarabine|fludarabine|mesh-list
102531397|NCT03602612|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102531398|NCT03602612|Immunologic Factors|immunologic factors|mesh-ancestor
102531399|NCT03602612|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102531400|NCT03602612|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102531401|NCT03602612|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102531402|NCT03602612|Alkylating Agents|alkylating agents|mesh-ancestor
102531403|NCT03602612|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102531404|NCT03602612|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102531405|NCT03602612|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102514160|NCT05070156|Immunologic Factors|immunologic factors|mesh-ancestor
102514161|NCT05070156|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102540812|NCT03029273|Cyclophosphamide|cyclophosphamide|mesh-list
102540813|NCT03029273|Fludarabine|fludarabine|mesh-list
102540814|NCT03029273|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102540815|NCT03029273|Immunologic Factors|immunologic factors|mesh-ancestor
102540816|NCT03029273|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102540817|NCT03029273|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102540818|NCT03029273|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102540819|NCT03029273|Alkylating Agents|alkylating agents|mesh-ancestor
102540820|NCT03029273|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102540821|NCT03029273|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102540822|NCT03029273|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102541817|NCT04499573|Dexamethasone|dexamethasone|mesh-list
102541818|NCT04499573|Cyclophosphamide|cyclophosphamide|mesh-list
102541819|NCT04499573|Fludarabine|fludarabine|mesh-list
102541820|NCT04499573|Etoposide|etoposide|mesh-list
102541821|NCT04499573|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102541822|NCT04499573|Immunologic Factors|immunologic factors|mesh-ancestor
102541823|NCT04499573|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102541825|NCT04499573|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102541826|NCT04499573|Alkylating Agents|alkylating agents|mesh-ancestor
102541827|NCT04499573|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102541828|NCT04499573|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102541829|NCT04499573|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102541830|NCT04499573|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102541831|NCT04499573|Antiemetics|antiemetics|mesh-ancestor
102541832|NCT04499573|Autonomic Agents|autonomic agents|mesh-ancestor
102541833|NCT04499573|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102541841|NCT04499573|Antimetabolites|antimetabolites|mesh-ancestor
102541842|NCT04499573|Antineoplastic Agents, Phytogenic|antineoplastic agents, phytogenic|mesh-ancestor
102541843|NCT04499573|Topoisomerase II Inhibitors|topoisomerase ii inhibitors|mesh-ancestor
102541844|NCT04499573|Topoisomerase Inhibitors|topoisomerase inhibitors|mesh-ancestor
102541845|NCT04499573|Antiviral Agents|antiviral agents|mesh-ancestor
102541846|NCT04499573|Anti-Infective Agents|anti-infective agents|mesh-ancestor
102566218|NCT05000450|Cyclophosphamide|cyclophosphamide|mesh-list
102566219|NCT05000450|Fludarabine|fludarabine|mesh-list
102566220|NCT05000450|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102566221|NCT05000450|Immunologic Factors|immunologic factors|mesh-ancestor
102566222|NCT05000450|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102566224|NCT05000450|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102566225|NCT05000450|Alkylating Agents|alkylating agents|mesh-ancestor
102566226|NCT05000450|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102566227|NCT05000450|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102566228|NCT05000450|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102550532|NCT04827745|Blinatumomab|blinatumomab|mesh-list
102550533|NCT04827745|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102551687|NCT04003649|Nivolumab|nivolumab|mesh-list
102551689|NCT04003649|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102551690|NCT04003649|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102551691|NCT04003649|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102541816|NCT04499573|Cytarabine|cytarabine|mesh-list
102541834|NCT04499573|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102541835|NCT04499573|Glucocorticoids|glucocorticoids|mesh-ancestor
102541836|NCT04499573|Hormones|hormones|mesh-ancestor
102541837|NCT04499573|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102541838|NCT04499573|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102541839|NCT04499573|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102541840|NCT04499573|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102616894|NCT04608487|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102558077|NCT00586391|Ipilimumab|ipilimumab|mesh-list
102558078|NCT00586391|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102558079|NCT00586391|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102558080|NCT00586391|Immune Checkpoint Inhibitors|immune checkpoint inhibitors|mesh-ancestor
102558081|NCT00586391|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102558509|NCT05445011|Cyclophosphamide|cyclophosphamide|mesh-list
102558510|NCT05445011|Fludarabine|fludarabine|mesh-list
102558511|NCT05445011|Fludarabine phosphate|fludarabine phosphate|mesh-list
102558512|NCT05445011|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102558513|NCT05445011|Immunologic Factors|immunologic factors|mesh-ancestor
102558514|NCT05445011|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102558515|NCT05445011|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102558516|NCT05445011|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102558517|NCT05445011|Alkylating Agents|alkylating agents|mesh-ancestor
102558518|NCT05445011|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102558519|NCT05445011|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102558520|NCT05445011|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102558521|NCT05445011|Antimetabolites, Antineoplastic|antimetabolites, antineoplastic|mesh-ancestor
102558522|NCT05445011|Antimetabolites|antimetabolites|mesh-ancestor
102565546|NCT05257083|Dexamethasone|dexamethasone|mesh-list
102565547|NCT05257083|Cyclophosphamide|cyclophosphamide|mesh-list
102565548|NCT05257083|Fludarabine|fludarabine|mesh-list
102565549|NCT05257083|Lenalidomide|lenalidomide|mesh-list
102565550|NCT05257083|Bortezomib|bortezomib|mesh-list
102565551|NCT05257083|Daratumumab|daratumumab|mesh-list
102565552|NCT05257083|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102565553|NCT05257083|Immunologic Factors|immunologic factors|mesh-ancestor
102565554|NCT05257083|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102565555|NCT05257083|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102565556|NCT05257083|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102565557|NCT05257083|Alkylating Agents|alkylating agents|mesh-ancestor
102565558|NCT05257083|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102565559|NCT05257083|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102565560|NCT05257083|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102565561|NCT05257083|Anti-Inflammatory Agents|anti-inflammatory agents|mesh-ancestor
102565562|NCT05257083|Antiemetics|antiemetics|mesh-ancestor
102565563|NCT05257083|Autonomic Agents|autonomic agents|mesh-ancestor
102565564|NCT05257083|Peripheral Nervous System Agents|peripheral nervous system agents|mesh-ancestor
102565565|NCT05257083|Gastrointestinal Agents|gastrointestinal agents|mesh-ancestor
102565566|NCT05257083|Glucocorticoids|glucocorticoids|mesh-ancestor
102565567|NCT05257083|Hormones|hormones|mesh-ancestor
102565568|NCT05257083|Hormones, Hormone Substitutes, and Hormone Antagonists|hormones, hormone substitutes, and hormone antagonists|mesh-ancestor
102565569|NCT05257083|Antineoplastic Agents, Hormonal|antineoplastic agents, hormonal|mesh-ancestor
102565570|NCT05257083|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
102565571|NCT05257083|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
102565572|NCT05257083|Growth Substances|growth substances|mesh-ancestor
102565573|NCT05257083|Growth Inhibitors|growth inhibitors|mesh-ancestor
102566125|NCT05032820|Lenalidomide|lenalidomide|mesh-list
102566126|NCT05032820|Immunologic Factors|immunologic factors|mesh-ancestor
102566127|NCT05032820|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102566128|NCT05032820|Angiogenesis Inhibitors|angiogenesis inhibitors|mesh-ancestor
102566129|NCT05032820|Angiogenesis Modulating Agents|angiogenesis modulating agents|mesh-ancestor
102566130|NCT05032820|Growth Substances|growth substances|mesh-ancestor
102566131|NCT05032820|Growth Inhibitors|growth inhibitors|mesh-ancestor
102566132|NCT05032820|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102616888|NCT04608487|Cyclophosphamide|cyclophosphamide|mesh-list
102616889|NCT04608487|Fludarabine|fludarabine|mesh-list
102616892|NCT04608487|Immunologic Factors|immunologic factors|mesh-ancestor
102616893|NCT04608487|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102616895|NCT04608487|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102616896|NCT04608487|Alkylating Agents|alkylating agents|mesh-ancestor
102616897|NCT04608487|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102616898|NCT04608487|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102616899|NCT04608487|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102616900|NCT04608487|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102617229|NCT03676504|Cyclophosphamide|cyclophosphamide|mesh-list
102617230|NCT03676504|Fludarabine|fludarabine|mesh-list
102617231|NCT03676504|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102617232|NCT03676504|Immunologic Factors|immunologic factors|mesh-ancestor
102617233|NCT03676504|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102617234|NCT03676504|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102617235|NCT03676504|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102617236|NCT03676504|Alkylating Agents|alkylating agents|mesh-ancestor
102617237|NCT03676504|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102617238|NCT03676504|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102617239|NCT03676504|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102623509|NCT04406610|Immunomodulating Agents|immunomodulating agents|mesh-list
102623511|NCT04406610|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102634394|NCT05256641|Acalabrutinib|acalabrutinib|mesh-list
102634395|NCT05256641|Tyrosine Protein Kinase Inhibitors|tyrosine protein kinase inhibitors|mesh-list
102634397|NCT05256641|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
102634398|NCT05256641|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102634399|NCT05256641|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102634650|NCT04735471|Cyclophosphamide|cyclophosphamide|mesh-list
102634651|NCT04735471|Fludarabine|fludarabine|mesh-list
102634652|NCT04735471|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102634653|NCT04735471|Immunologic Factors|immunologic factors|mesh-ancestor
102634654|NCT04735471|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102634655|NCT04735471|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102634656|NCT04735471|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102634657|NCT04735471|Alkylating Agents|alkylating agents|mesh-ancestor
102634658|NCT04735471|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102634659|NCT04735471|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102634660|NCT04735471|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102641581|NCT04257578|Acalabrutinib|acalabrutinib|mesh-list
102641583|NCT04257578|Tyrosine Protein Kinase Inhibitors|tyrosine protein kinase inhibitors|mesh-list
102641584|NCT04257578|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102641585|NCT04257578|Protein Kinase Inhibitors|protein kinase inhibitors|mesh-ancestor
102641586|NCT04257578|Enzyme Inhibitors|enzyme inhibitors|mesh-ancestor
102641587|NCT04257578|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102641588|NCT04257578|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102647482|NCT05464719|Loncastuximab tesirine|loncastuximab tesirine|mesh-list
102647483|NCT05464719|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102647484|NCT05464719|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102648560|NCT04432506|Cyclophosphamide|cyclophosphamide|mesh-list
102648561|NCT04432506|Fludarabine|fludarabine|mesh-list
102648562|NCT04432506|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102648563|NCT04432506|Interleukin 1 Receptor Antagonist Protein|interleukin 1 receptor antagonist protein|mesh-list
102648564|NCT04432506|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102648565|NCT04432506|Immunologic Factors|immunologic factors|mesh-ancestor
102648566|NCT04432506|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102648567|NCT04432506|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102648568|NCT04432506|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102648569|NCT04432506|Alkylating Agents|alkylating agents|mesh-ancestor
102648570|NCT04432506|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102648571|NCT04432506|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102648572|NCT04432506|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102648573|NCT04432506|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102648959|NCT04071366|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102648960|NCT04071366|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102648961|NCT04071366|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102344006|NCT04025216|Cyclophosphamide|cyclophosphamide|mesh-list
102344007|NCT04025216|Fludarabine|fludarabine|mesh-list
102344008|NCT04025216|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102344009|NCT04025216|Immunologic Factors|immunologic factors|mesh-ancestor
102344010|NCT04025216|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102344011|NCT04025216|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102344012|NCT04025216|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102344013|NCT04025216|Alkylating Agents|alkylating agents|mesh-ancestor
102344014|NCT04025216|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102344015|NCT04025216|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102344016|NCT04025216|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102346097|NCT04789408|Cyclophosphamide|cyclophosphamide|mesh-list
102346098|NCT04789408|Fludarabine|fludarabine|mesh-list
102346099|NCT04789408|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102346100|NCT04789408|Immunologic Factors|immunologic factors|mesh-ancestor
102346101|NCT04789408|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102346102|NCT04789408|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102346103|NCT04789408|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102346104|NCT04789408|Alkylating Agents|alkylating agents|mesh-ancestor
102346105|NCT04789408|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102346106|NCT04789408|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102346107|NCT04789408|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102346449|NCT04318678|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102346450|NCT04318678|Immunologic Factors|immunologic factors|mesh-ancestor
102346451|NCT04318678|Physiological Effects of Drugs|physiological effects of drugs|mesh-ancestor
102346452|NCT04318678|Antirheumatic Agents|antirheumatic agents|mesh-ancestor
102346453|NCT04318678|Antineoplastic Agents, Alkylating|antineoplastic agents, alkylating|mesh-ancestor
102346454|NCT04318678|Alkylating Agents|alkylating agents|mesh-ancestor
102346455|NCT04318678|Molecular Mechanisms of Pharmacological Action|molecular mechanisms of pharmacological action|mesh-ancestor
102346456|NCT04318678|Antineoplastic Agents|antineoplastic agents|mesh-ancestor
102346457|NCT04318678|Myeloablative Agonists|myeloablative agonists|mesh-ancestor
102346458|NCT04318678|Antineoplastic Agents, Immunological|antineoplastic agents, immunological|mesh-ancestor
102616890|NCT04608487|Axicabtagene ciloleucel|axicabtagene ciloleucel|mesh-list
102616891|NCT04608487|Immunosuppressive Agents|immunosuppressive agents|mesh-ancestor
102346448|NCT04318678|Fludarabine|fludarabine|mesh-list
